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ABSTRACT 
Adenovirus (AdV) infection is ubiquitous in the human population and causes acute 
infection in the respiratory and gastrointestinal tracts. In addition to lytic infections in epithelial 
cells, AdV can persist in a latent form in mucosal lymphocytes, and nearly 80% of children contain 
viral DNA in the lymphocytes of their tonsils and adenoids. Reactivation of latent AdV is thought 
to be the source of deadly viremia in pediatric transplant patients. Adenovirus latency and 
reactivation in lymphocytes is not well-studied, though immune cell activation has been reported 
to promote productive infection from latency. In lymphocytes, programs of gene expression during 
both resting and activated states have been shown to be regulated in part by chromatin remodelers 
and co-repressors, including Class I and II histone deacetylases (HDACs), Class III HDACs 
(sirtuins), and the C-terminal Binding Protein Family (CtBPs). Because the adenovirus genome is 
chromatinized through rapid association with cellular histones upon entry into the host cell 
nucleus, viral gene expression is potentially regulated by these same cellular chromatin-modifying 
mechanisms and responsive to immunoactivation of the host lymphocyte. In this doctoral work, 
we show that enzymatic activity of Class I HDACs and sirtuins, but not Class II HDACs, contribute 
to the repression of viral early and late genes during persistent infection. We also show that 
modulation of cellular NAD+/NADH can de-repress adenovirus gene expression in persistently-
infected lymphocytes. In contrast, disrupting the NAD-dependent CtBP repressor complex 
interaction with PxDLS-containing binding partners paradoxically alters AdV gene expression.    
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1 INTRODUCTION 
     This doctoral thesis focuses on mechanisms of transcriptional regulation of adenovirus 
(AdV) persistent infection in lymphocytes. In this introductory chapter, a brief overview of the 
human adenoviruses will be given with rationale for the study of AdV Species C in connection 
with persistent infection. An overview of the sequential steps occurring in the lytic infection of 
epithelial cells will then be compared to what is known for persistent infection described in cell 
lines models and primary lymphocytes. Because our studies have focused on mechanisms of gene 
expression regulation, a review of what is known of viral chromatin structure in lytic and persistent 
infection and in the context of adenoviral vector transgene delivery will be given. This chapter will 
conclude with a review of known mechanisms of transcriptional regulation of the adenovirus 
genome, with rationale for the overarching hypothesis for this work.     
1.1 Human Adenoviruses 
     Human adenoviruses were discovered in 1953 by Rowe et al. as the cytopathogenic 
agent present in cultured adenoid tissues (1) and independently by Hilleman et al. as a cause of an 
acute respiratory disease outbreak among military personnel (2). Since then, the viruses of the 
family Adenoviridae have been found in all major classes of vertebrates, with the genus 
Mastadenovirus containing mammalian adenoviruses including the seven species (A-G) found in 
human hosts (3). Currently there are more than 85 types of human AdV that have been identified 
through serotyping and genomic analysis (4-6). Human AdV infections cause a variety of different 
diseases including conjunctivitis (A, B, E), gastroenteritis (A, F, G), and respiratory disease (B, C, 
E) (3). 
     Infections with Species C (types 1 and 2) were among the AdVs most reported in a 2017 
survey in the U.S. (7), and these along with Species C type 5 are most commonly associated with 
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symptomatic respiratory infections (8). AdV-C infections predominantly occur in very young 
children and are a major cause of respiratory disease in pediatric patients (9-12). In a study of 
extracted tonsils or adenoids, approximately 80% of patients under age 19 contained AdV-C (types 
1, 2, 5, and 6) DNA in lymphocytes of those tissues, most in a non-replicating state (10). In 
addition, AdV-C are responsible for more than half of adenovirus infections and severe disease in 
immunocompromised patients (6,11). Pediatric patients receiving hematopoietic stem cell 
transplants (HSCT) are at significant risk for developing disseminated AdV infection, with AdV-
related post-transplantation mortality between 3.2 and 6.0%, or approximately 100 children per 
year in the U.S. (13,14). These infections can result from de novo exposure to the virus, but 
reactivation of latent adenovirus from the patient’s own tissues is the predominant cause for the 
most severely immunocompromised patients (14). The mechanisms allowing the virus to persist 
and the conditions inducing reactivation of the virus are almost entirely unknown. This gap in 
knowledge has proven to be a critical barrier to preventing AdV-related disease in transplant 
recipients. 
     As AdV-C is the predominant species associated with the latent or persistent infection 
of mucosal tissues of the tonsils, adenoids, and gastrointestinal tract (10,15), the mechanisms 
governing the persistent AdV-C infection in lymphocytes are the focus of this work. Our study 
will be the first work to investigate and describe how cellular transcriptional regulators are 
involved in maintenance of persistent adenovirus infection in lymphocytes. Understanding the 
mechanisms for adenoviral persistence may provide novel targets for therapies to prevent 
reactivation and disseminated adenoviral infection in pediatric HSCT recipients. 
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1.2 Viral Structure, Life Cycle, and Tropism 
AdVs are 90nm, non-enveloped viruses with 36kB linear, double-stranded DNA genomes 
(3). The viral DNA is condensed into the viral particles by basic viral protein µ and packaged by 
major core protein VII (16) (Figure 1-1). The capsid of the virus consists largely of a hexon protein 
icosahedral shell with penton base proteins attached to protruding fiber proteins at the vertices (16) 
(Figure 1-1). No host-cell proteins have been found to be associated with the viral particles (3). 
 
Figure 1-1. Structure of an Adenovirus Particle.  
                                 Adapted from (16). 
 
1.2.1 Lytic Infection  
Epithelial cells are the primary target for AdV, and adsorption of the virus occurs when the 
fiber protein attaches to the cellular protein coxsackie-adenovirus receptor (CAR) on the 
membrane of the host cell. A secondary attachment via the RGD-motif in the penton base protein 
to an avb3/5 integrin triggers clathrin-mediated endocytosis and the initial stages of disassembly of 
the virus (16-19). Following release from the endosomes, the partially uncoated virus is transported 
by microtubules to the nuclear pore (3). The viral genome, bound only to core protein VII, enters 
the host cell nucleus where it is quickly chromatinized through association with cellular histones 
(20).  
Upon expression of viral early genes and virally associated (va) RNAs I and II, the cellular 
antiviral defenses are blocked, and cellular gene expression and metabolism are dramatically 
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altered to generate metabolic precursors and to drive the cell into S-phase (21,22). Following 
replication of the viral genome, the late stage of infection begins with inhibition of cellular protein 
translation and production of viral structural proteins. Viral particles assemble in the nucleus, and 
the host cell is lysed to release thousands of viral progeny (Figure 1-2) (3,22). 
1.2.2 Persistent Infection 
Despite the some-what ironic fact that AdVs were discovered through persistent infection 
of adenoids (1), the steps leading to the establishment of persistent AdV infection and mechanisms 
of reactivation are currently almost entirely unknown. Early epidemiological studies showed that 
AdV could be detected intermittently in patient fecal samples for months to years after resolution 
of symptoms, indicating the presence of some viral reservoir in the host (23).  As mentioned above, 
it is now understood that the persistent adenovirus infection occurs in lymphocytes, and 
predominantly T cells, of the tonsils, adenoids, and GI tract, with the majority of viral genomes 
present in a non-replicating state (10,15).  
     Unlike infection of epithelial cells, species C adenoviruses infect lymphoid cells with 
very different and less-studied infection kinetics. Infection of these cells begins with attachment 
to the avb3/5 integrins alone, as most hematopoietic cells do not express CAR (18,24,25). While no 
studies have reported on the mechanism of entry in lymphocytes, internalization may be governed 
by different mechanisms than in epithelial cells (26), and other mechanisms such as caveolae- and 
macropinocytosis-mediated endocytosis of adenovirus particles have been reported in various cell 
types when CAR is not the primary receptor (27,28). The next steps of uncoating and transport of 
the genome to the nucleus have also not been studied in lymphocytes, but unusually low expression 
of viral proteins has been reported in T cell lines in which the quantities of internalized virus 
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appeared normal, indicating that steps of the early life cycle in lymphocytes may deviate from 
those in epithelial cells as early as post-internalization (25).  
Persistent infection of lymphocytes typically does not progress to lysis but rather to a non-
lytic, “smoldering” infection in which replicating virus is rare (10,13,29).  Immunoactivation of 
infected primary lymphocytes has been shown to induce production of infectious virus, showing 
that persistence and reactivation may be closely tied to the active state of the lymphocyte (10). In 
order to circumvent the challenges of obtaining naturally-infected primary lymphocytes from 
patient samples to study, lymphocytic cell-line models of persistent infection have been developed 
which harbor viral DNA for months in culture (13,29).  These models of persistent infection also 
contain low levels of replicating virus, albeit at slightly higher levels than infected primary cells 
(13,29), and release low amounts of virus detectable through extraction of DNA from culture 
supernatants or application of supernatants onto permissive cell lines ((13) and our unpublished 
results). Viability of these persistently-infected cell lines remains unaffected (13,29),  indicating 
either very few cells are lysing to release the viral particles, or an as-of-yet unidentified mechanism 
for egress is occurring (Figure 1-2).  
The persistent infection in these lymphocytic cell-line models has been shown to be 
regulated, in part, by as-of-yet uncharacterized transcriptional controls not detectable in lytic 
infection of epithelial cells (see Section 1.3.2 - AdV Genome Organization and Overview of 
Transcriptional Program below for more detail). Murali et al. (2014) determined that the early 
gene E3-Adenovirus Death Protein (ADP), which is critical for cell lysis, was repressed both 
transcriptionally and post-transcriptionally in cells which maintain the persistent infection (30). 
Krzywkowski et al. (2017) showed that in a persistently-infected B cell line very few individual 
cells expressed quantities of immediate early gene E1A mRNA or late gene mRNA comparable to 
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lytically-infected HeLa cells, even in cells with large amounts of viral DNA (31). Furuse et al. 
(2013) determined vaRNAs I and II were expressed in comparable amounts between persistently-
infected B cells and lytically-infected epithelial cells, but in different relative proportions (32).  
These few studies suggest a specific program of repression is needed to maintain the persistent 
infection, but further work is needed for more complete characterization.  
 
 
Figure 1-2. Comparison of events and tropism of lytic and persistent infection. 
 
1.3 Chromatin Structure of AdV Genome 
Despite the large body of work describing the impact of adenovirus infection on cellular 
chromatin, the role of chromatin in regulation of expression from the viral genome itself has been 
less well-studied.  The following sections will begin with an overview of the organization of the 
viral genome, then document what has been reported on chromatin structure and transcriptional 
regulation of viral gene expression in the context of lytic and persistent infections. Additionally, 
regulation of transgene expression from adenoviral vectors will be discussed.   
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1.3.1 AdV Genome is Episomal 
Unlike the genomes of other DNA viruses which integrate into the host cell DNA (33-36), 
adenovirus genomes, both wild-type and vector DNA, remain episomal except for extremely rare 
instances (29,37-40). The mechanisms which prevent integration have not been identified, but this 
characteristic of adenoviral DNA has promoted its use as a viral vector for transgene delivery (40).  
Avoiding integration may be an evolutionary advantage for the virus, as integration of foreign 
DNA triggers de novo methylation and gene silencing as part of an ancient cellular antiviral 
defense (41-43).  In vitro methylation of the integrated E1A promoter in HEK293 cells showed 
reduced expression of E1A (44), but whether this is biologically relevant has not been determined 
as no DNA methylation has been reported for the episomal adenovirus genome (45).  
1.3.2 AdV Genome Organization and Overview of Transcriptional Program 
The program of viral transcription in lytic infection is well-documented and is primarily 
orchestrated through coordination by the E1A proteins. Historically, E1A has been reported the 
first transcript expressed from the viral genome, which is alternatively spliced into two principle 
variants, 13S and 12S, giving rise to the 289R and 243R proteins, respectively.  Through a recent 
study tracking viral transcription in normal lung fibroblasts, it is now understood that non-coding 
vaRNAs I and II, which inhibit the dsRNA-sensor protein kinase R (PKR), are first expressed, 
followed quickly by expression of E1A and E4 (21).  The viral early genes, E1B, E2, and E3 are 
next expressed which prepare the cell for viral DNA replication by blocking apoptosis, producing 
the viral polymerase and essential replication proteins, and tamping down the host-cell immune 
response, respectively (46). Following mass production of viral DNA, the late genes are expressed 
which largely encode structural and packaging proteins (3).  The double-stranded AdV DNA 
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genome and main transcription units are shown in Figure 1-3.  The major proteins from the 
transcription units and their functions are shown in Table 1-1.   
 
 
Figure 1-3.  Genomic organization of AdV-C5. 
The linear double-stranded DNA genome is depicted as a thin line, 5’ to 3’, with the 
inverted terminal repeats (ITR) at each end: lengths are marked in kbps. Transcription units are 
shown relative to their position and orientation. Early genes (gray bars): E1A, E1B, E2A/B, E3, 
and E4. Intermediate genes (orange bars): IX and Iva2. Late genes (green bars): L1-L5, produced 
from the major late promoter (MLP). Open rectangles denote introns. Late genes (L1-L5) produced 
from the MLP all contain the tripartite leader (TPL) at their 5’ ends. Modified from (47) and (48). 
 
1.3.3 Chromatin Structure during Lytic Infection 
While viral DNA interacts with several viral core proteins in the formation of infectious 
particles (Figure 1-1), only protein VII remains associated with the viral genome from packaged 
state in the viral capsid to the host cell nucleus (66). The interaction between VII and the viral 
DNA serves multiple purposes. Protein VII is a core basic protein that was originally believed to 
be essential for compacting the viral genome into the capsid (67). Recent work using viruses 
lacking the late VII gene showed protein VII was not essential for encapsidation, but played a more 
important role in pressurizing the core and genome release (68). Upon entry of the viral genome 
into the nucleus, VII monomers are spaced across the DNA similarly to histones across cellular 
DNA, a structure that protects the viral DNA from activating the DNA damage response (69). 
Protein VII from the incoming viral particle remains associated with the viral chromatin  
 
5" 10" 15" 20" 25" 30" 35"
ITR" ITR"
packaging(
E1A"E1B" E3"
E4"E2A"
E2B"
IVa2"
IX" L1" L2" L3" L4" L5"MLP"
Gene/ 
Transcription 
Unit 
Corresponding 
Protein(s) 
Role in Viral Life 
Cycle 
First early - E1A E1A-13s & 12s Early gene activation Induction of S-phase 
Early – E3 E3gp19K Blocks MHC-I presentation 
Late – L3 Hexon Structural - Capsid 
!
VA I, II
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Table 1-1. Major protein products and their functions from AdV transcription units. 
** denotes genes falling within the early gene region, but expressed at intermediate time 
points. References for all proteins from each gene as indicated.  
 
 
 
 
 
Early 
Gene Protein Function 
Late 
Gene Protein Function 
E1A E1A-289R Activate early 
genes 
L1 52/55K Packaging 
 E1A-243R Induce cell cycle  pIIIa Packaging 
  (49)   (50) 
E1B 19K Inhibit apoptosis L2 penton Capsid/attachment 
 55K Inhibit p53, Ub 
pathway 
 pVII DNA condensation 
 IX** Capsid stability  pV Secure DNA to 
capsid 
  (51),(52),(52)  pX (µ) DNA condensation 
E2 DBP DNA replication   (53),(54),(55),(56) 
 pTP Primes DNA 
polymerase 
L3 pVI Endosome lysis 
 pol Viral DNA 
polymerase 
 hexon Capsid 
 Iva2** Packaging, ATPase  protease Maturation of 
structural proteins 
  (57),(58)   (50),(59),(60) 
E3 12.5K Unknown L4 100K ¯ translation shut-
off 
 6.7K Inhibit apoptosis  22K Packaging 
 gp19K MHC escape  33K Splicing, packaging 
 ADP Cell lysis/egress  pVIII Hexon stabilization 
 RID-! ¯ TNF, Fas, 
TRAIL 
  (61),(62),(58) 
 
 RID-b ¯ TNF, Fas, 
TRAIL 
L5 fiber Attachment 
  (46), (30)   (53) 
E4 Orf1 Unknown    
 Orf2 Unknown    
 Orf3 ¯ host translation, 
chromatin remodel 
   
 Orf4 Splicing viral RNA    
 Orf4-34K Packaging    
 Orf6 ¯ host translation, 
Ub pathway 
   
 Orf6/7 mRNA export, 
transcription 
   
  (63),(64),(52),(48)    
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throughout the early phase of infection and is also important for E1A transactivation of early genes 
(70).  
The viral DNA/protein VII-chromatin structure that enters the nucleus must be quickly 
remodeled to allow for efficient transcription of viral genes (71,72). Some protein VII is lost to  
accommodate incorporation of cellular histones into the viral chromatin, and replication-
independent variant H3.3 and other core histones become localized throughout most promoter and 
protein-coding regions (73,74). Although sites of high levels of protein VII binding on the viral 
DNA correlate with gene repression (75,76), low levels of VII can enhance transcription, likely 
through chromatin remodeling by interaction with template-activating factor 1𝛽 (TAF-1𝛽) and 
nuclear phosphoprotein pp32 (members of the SET nucleosome assembly complex and inhibitor 
of histone acetyltransferases [INHAT] complex, respectively) (70,72,73,77). Because increases in 
acetylation of H3 can be detected as viral promoters become active, the remodeled viral chromatin 
structure appears to be similar to cellular chromatin, subjecting it to regulation by the cellular 
machinery (20). 
Recent work has shown that interactions between the host and viral chromatin may also be 
important to the program of viral gene expression. Studies using Hi-C analysis and tethered 
chromosome conformation capture (TCC) to detect positioning of the viral chromatin show that 
AdV DNA interacts predominately with the transcription start sites (TSSs) and enhancers of highly 
active cellular chromatin (78,79). The viral genome associates with genes that are upregulated 
during the course of infection, suggesting that the temporal changes in cellular gene expression 
that occur may be linked with sequential expression of viral genes (79). Besides colocalization of 
viral DNA and active cellular DNA, some additional interactions between the viral and host cell 
chromatin were surprisingly found to be enriched at regions high in heterchromatic histone marker 
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H3K27me (78). This  histone marker is usually associated with repression mediated by the 
Polycomb repressive complex (PRC) (80).  Interestingly, the PRC complex plays a role in 
regulation of latency of other DNA viruses, but whether or not  PRC-based repression is involved 
in adenovirus lytic or persistent infection has not been determined (81). 
1.3.4 Chromatin Structure of AdV Vectors 
The AdV DNA backbone is commonly used as a vehicle for gene-therapy and oncolysis 
because of the extensive knowledge available about the lytic life cycle and genomic elements and 
the relatively low safety risk (82). However, it is clear that suboptimal, cell type-dependent 
conditions are a common challenge that must be overcome to effectively use AdVs as a delivery 
mechanism.  In fact, in cells that are not the primary wild-type adenoviral targets, AdV vectors 
lose long-term transgene expression, mirroring some aspects of the persistent infection in 
lymphocytes (83). Mechanisms that have been reported for repression of gene expression in these 
systems may be important to consider in understanding the full repertoire of regulators involved 
in directing the fate of the viral genome for wild-type viruses.  
     Like wild-type viral genomes of lytic infection, AdV vectors also are associated with 
protein VII and cellular histones early in infection (84,85). This association with histones has been 
shown to be important for establishing the needed chromatin structure for transgene expression 
(85).  However, even in the absence of all functional viral proteins, over time, transgene expression 
from adenovirus vectors can be diminished through remodeling of the vector chromatin induced 
by innate immune responses to the presence of the foreign DNA. Histone deacetylase inhibitors 
(HDACi) can upregulate expression of transgenes delivered in vectors of several different viral 
backgrounds, showing that non-specific hypoacetylation may be a mechanism of defense (86).  
Suzuki et al. (2010) showed that TLR (Toll-like Receptor)-MyD88 signaling played a role in 
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reduced expression of a transgene through a decrease in the active chromatin mark H3K9Ac 
relative to the heterchromatic mark H3K9me2 (85,87), but future work is needed to identify the 
details of the pathway and the enzymes involved.   
1.3.5 Chromatin Structure during Persistent Infection 
The chromatin structure of the viral genome in persistent infection is largely unstudied.  
Unlike AdV-vector DNA, which often has viral genes mutated or excised, wild-type genomes with 
fully intact viral genes establish persistent infection (10).  The normal progression of viral gene 
expression is delayed in all lymphocyte cell-line models of infection relative to infection in 
epithelial cells (29), but whether this is a result of suboptimal chromatin structure has not been 
studied. Considering that both genomes of lytic infection and viral vectors associate with cellular 
histones (20), and that viral transcripts can be detected in persistently infected cells (10,31,32), the 
in-coming viral chromatin/VII structure is likely remodeled to include cellular histones at least to 
some degree. We also recently reported that AdV gene expression in persistent infections is 
responsive to treatment with HDAC inhibitor trichostatin A (TSA) (Wilms et al., submitted) 
further supporting a role for histones and their modification in the chromatin structure. In a recent 
study using a padlock probe-based rolling-circle amplification (RCA) to evaluate concurrent AdV 
DNA and mRNAs in single epithelial or lymphocytic cells, viral DNA could not be detected in 
lymphocytes expressing low amounts of viral mRNA (31). This was interpreted to be a result of 
protein VII interference with probe binding (31), and suggests that at least some lymphocytes 
contained viral genomes which lacked proper chromatin remodeling for gene expression.  
1.4 Transcriptional Regulation of Viral Gene Expression 
In additional to the chromatin structure itself, a second level of regulation of viral gene 
expression involves activities of cellular and viral proteins in chromatin modification and 
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recruitment of transcriptional complexes to promoters of the viral genes. This section will begin 
by describing the activity of the best-known transcriptional regulator of AdV gene expression, the 
viral E1A-289R protein. Then key cellular enzymes and proteins that have been found to play a 
role in regulation of transcription of viral genes in lytic infections and expression of AdV vector 
transgenes will be discussed. This section will conclude with the statement of hypothesis for this 
dissertation, concerning transcriptional regulation of viral gene expression in persistent infection 
in lymphocytes. 
1.4.1 Viral E1A-289R 
The AdV E1A-289 protein, the larger of the two E1A isoforms (Figure 1-4), is the single-
most important protein in transcriptional regulation of the viral genome owing to its function of 
transactivating the full repertoire of early genes (88).  E1A-289R has no intrinsic DNA-binding 
capacity, but through interaction with cellular transcription factors recruits the basal transcriptional 
machinery and regulatory complexes to the early gene promoters (90).  Essential to the 
 
 
Figure 1-4. Adenovirus E1A major isoforms. 
289R (translated from a 13S mRNA transcript) and 243R (translated from a 12S mRNA 
transcript). CR: regions of E1A that are conserved across many adenovirus serotypes. CR3 is 
unique to E1A-289R. Figure modified from (89). 
 
 
transactivational function of E1A-289R is the interaction between CR3 and the MED23/Mediator 
complex (91), a 30-unit transcriptional co-activator involved in many aspects of transcriptional 
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regulation including chromatin remodeling and mRNA processing (92). Mediator is thought to 
establish enhancer-promoter loops, and also is important for transcription initiation (92). Figure  
1-5 depicts the E1A-289R/Mediator-regulated transactivation of the AdV early genes. 
 
 
Figure 1-5. E1A-289R transactivation of AdV early genes. 
The solid black line represents the viral genome (not drawn to scale), and the relative 
locations of the viral early genes are shown. The first viral protein produced is E1A-289R, which 
then auto-activates viral gene E1A (solid gray line). Similar E1A-containing complexes then move 
to promoters of and activate viral early genes E4, E3, E1B, and E2 (dashed gray lines) (93). DBF: 
any of several cellular DNA-binding factors. 
 
While the CR3 region of E1A-289R recruits the mediator complex, the activity of this 
complex has the potential to be further modified through the multitude of interactions E1A-289R 
has with additional cellular proteins (49). Figure 1-6 shows many of the E1A-289R binding 
partners, including transcription factors, histone acetyltransferases, co-repressors, transcriptional 
machinery, and chromatin remodelers (modified from (90)). Binding sites for the transcription 
factors that interact with E1A-289R, and many others, can be found in the promoters of the early 
genes.  Table 1-2 lists the transcriptional regulatory elements in each of the responsive viral 
promoters, and the degree to which E1A-289R upregulates expression. 
 
 
E1A E1B
E2
E3
E4
DBF
Transcription 
Mediator 
ComplexE1A
Adenovirus Genome
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Figure 1-6. Conserved regions of E1A-289R and their cellular binding partners. 
Modified from (90). 
 
In a very interesting new finding, E1A-289R transactivation of early genes E1B, E2 and 
E3 was surprisingly found to be regulated in part by the interaction between E1A-289R and the 
E4orf3 protein (109).  E4orf3 functions largely to silence the stress response induced by viral 
infection through the non-specific induction of heterochromatin formation, inadvertently silencing 
viral genomes as well (110).  Soriano et al. (2019) found the interaction between E1A and E4orf3 
serves to fine-tune transactivation of the early genes: E1A counteracted the induction of 
heterochromatin formation on the viral genome induced by E4orf3, and E4orf3 interacted with 
E1A to increase occupancy of E1A and transactivational complexes at the early gene promoters.  
 
 
 
CR4
16 
Table 1-2. Transcription factor binding sites and regulatory elements in E1A-responsive 
viral promoters. 
 
Adenovirus Promoter
Transcription 
Factor/Regulatory 
Element
Position 
Relative to 
TSS (bps)
Reference(s)
E1A TATA Box -21 to -38 (94)
Self upregulates 4-fold (88) ATF -36 to -83
-91 to -99
-338 to -319
-414 to -391
-450 to -428
(94)
OCT1 -197 to - 181 (94)
E2F -293 to -221 (94)
E1A-F (ETV4) -273 to -257
-304 to -289
-346 to -334
-394 to -375
(94)
SP1 -420 to -391
-447 to -442
(94)
PMA-responsive 
element
-237 to -47 (95)
E1B TATA-box -30 to -23 (96)
Sp1 (GC Box) -49 to-38 (97,98)
Sites I, II, III, IV -358 to -127 (99)
E2-Early Atypical TATA-box -30 to -25 (88)
E1A upregulates 10-fold 
(100) 
Atypical TBP -29 to -23 (101)
E2F -45 to -36
-67 to -60
(101)
ATF -76 to -69 (101)
E3 TATA box -33 to -7 (46)
Upregulated 30-fold by 
E1A (102)
NF-1 -183 to -154 (103)
NF-kB -155 to -137
-134 to -113
(104)
ATF -68 to -44 (103,105)
AP-1 -103 to -81 (103)
E4 TATA -25 (103)
100-fold increase by E1A 
(106)
ATF -50
-140
(47)
E4F1 -53 to -47
-146 to –141
-167 to -161
(107)
Major Late Promoter TATA-Box -33 to -22 (88)
E1A induces 10-30-fold 
upregulation (88)
USF -63 (108)
CP1 -76 (108)
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1.4.2 Histone Acetyltransferases (HATs): p300 and Tip60 
Histone acetyltransferase activity of p300, recruited through interaction with E1A-289R, 
has recently been shown to be critical to the chromatin remodeling at AdV early gene promoters 
(111). p300-induced increases in active marks H3K18ac and H3K27ac were seen at promoters for 
E2, E3, and E4. Interestingly, an increase in these active marks was also noted for the E1A 
promoter, suggesting a role for chromatin structure in regulation of this gene, despite speculation 
that chromatinization was less relevant for this promoter (112). p300-dependent acetylation had 
different effects on transcription at each viral promoter; initiation of transcription was dependent 
on acetylation at the E2 promoter, but post-initiation steps were affected at the E3 and E4 
promoters.   
     Tip60 (also known as KAT5), originally isolated and named as a cellular HIV-Tat 
interacting protein, is a MYST family lysine acetyltranferase which acts as a transcriptional 
regulator (113). Despite the known association between histone acetylation and active gene 
expression, Tip60 appears to act in a repressive role in the AdV transcriptional program. In a study 
by Gupta et al. (2013), Tip60 knock-down released repression of all AdV early genes, with a 3- to 
4-fold increase in E1A expression, but had no impact on the major late promoter (MLP) (hexon 
and fiber) (75). Further, Tip60 was found enriched at the TSS along with AdV protein VII and 
unexpectedly, increased H4Ac at repressed E1A promoters. These findings together show that 
carefully-regulated histone acetylation is important for optimal expression of AdV genes.   
1.4.3 Class I and II HDACs 
Despite the importance of HATs in AdV transcriptional regulation, little has been reported 
about the role for their enzymatic counterparts, the histone deacetylases (HDACs). Perhaps this is 
due, in part, to the rapid progression of the lytic infection where regulation of activation of viral 
18 
genes might be more relevant. For long-term persistent infections or retention of AdV vectors, 
HDACs may have a larger impact on gene expression.    
Silencing of transduced genes through the chromatinization of the AdV DNA vector 
backbone is a common challenge facing AdV-based oncolytic viral therapies (85). While HDAC 
inhibitors (HDACi) have been reported to increase the efficiency of oncolytic viral therapy through 
the increased expression of viral receptors on the cell surface (114), HDACi also have been 
reported to increase expression of genes delivered in the AdV vector (115,116). Various Class I 
and II HDACi have been used successfully to upregulate transgene expression in numerous cell 
types and lines from a range of host species, including primary bovine or rat muscle cells (117),  
human thyroid carcinoma cell lines (116), mouse neuroblastoma cells, HeLa cells, human 
neuroblastoma cells, primary human dendritic cells, keratinocytes, and primary rat astrocytes (86), 
and rat neurons (118). The broad diversity of vector constructs and the wide array of cellular 
backgrounds in which Class I and II HDACi increase gene expression suggest HDACs act in a 
non-specific manner to silence foreign DNA. 
We have recently reported that HDACs play a role in persistent infection with intact viral 
genomes as well; TSA upregulates transcription of several viral genes in persistently-infected 
lymphocytes (Wilms et al., manuscript submitted). The work in this dissertation provides 
additional insight for the involvement of Class I and II HDACs in persistent AdV infection, and 
shows that activity is targeted to specific viral genes (Chapter 3). 
1.4.4 Class III HDACs – Sirtuins 
Sirtuins (SIRT1-7), also called Class III HDACs,  are a family of nicotinamide adenine 
dinucleotide (NAD+)-dependent histone deacetylases with a variety of other enzymatic activities 
in the cell including ADP ribosylation, desuccinylation, and demalonylation (119). Sirtuins 
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function in many aspects of essential cellular processes such as chromatin remodeling and gene 
expression, apoptosis, and DNA repair (120). The NAD+-dependence of sirtuins also links function 
to the metabolic state of the cell (119).  Relevant to AdV transcriptional regulation and as yet 
uninvestigated, SIRT1 has been shown to deacetylate and thereby negatively regulate the HAT 
activity of p300 (120), which could in turn negatively regulate expression of AdV genes (111).   
     Sirtuins have been shown to have broad anti-viral activity, as siRNA knock-down of all 
seven sirtuins increases viral titers for both RNA and DNA viruses, including 1.5- to 3-fold 
increases in AdV-C5 titers (119). In the same vein, activation of sirtuins through resveratrol 
treatment inhibits adenovirus DNA replication of wild-type and vector viruses (118,121,122), but 
the mode of action has not been described. This doctoral work shows that sirtuins contribute to 
repression of AdV genes in persistently-infected lymphocytes (Chapter 3).  
1.4.5 Co-repressive C-terminal Binding Proteins (CtBPs) 
The CtBP family of transcriptional corepressors was discovered through their high affinity 
binding to AdV E1A proteins (123,124). Mammalian cells express both CtBP1 its homolog CtBP2 
(collectively known as CtBP) which can form homo- and hetero- tetrameric complexes, the 
assembly and stability of which are dependent on NAD(H) binding (125-128).  CtBP complexes 
can recruit many different chromatin modulators including Class I HDACs 1 and 2, histone 
methyltransferases, E3 ligases and other transcriptional regulators into large transcriptionally 
repressive complexes at the promoters of genes ((129), reviewed in (130)). As a result of the 
dependence on NAD(H) binding, CtBP has been reported to function as an NAD(H) sensor and 
therefore a link between metabolic state and transcriptional regulation (131-133). 
     The role of CtBP in the AdV lytic life cycle is complex, acting in a repressive or a 
potentiating capacity in a situational manner.  CtBP has been found to both repress and facilitate 
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E1A-289R and -243R-mediated transactivation of viral and cellular genes, respectively (134,135).  
CtBP1 and 2 have long been known to suppress the ras-cooperative transformative activity of 
E1A, but also appear to enhance E1A transcriptional regulation, possibly through suppression of 
the interferon response (123,136-138).  Both E1A-289R and -243R interact with high affinity to 
both CtBP1 and 2 through a PLDLS-motif located in the shared conserved region 4 (CR4) at the 
C-terminal end of the E1A proteins (Figure 1-4).  E1A-289R has an additional CtBP-interaction 
domain located in the CR3 region unique to this isoform (134), implicating CtBP in regulation of 
early genes. Of note, NADH was found to facilitate binding of CtBP to E1A at 1000-fold lower 
concentration than NAD+, suggesting that the NAD+/NADH ratio in the cell may affect the 
formation of CtBP-E1A protein complexes (131). We show in this doctoral work that CtBP may 
have an additional role in repression of E1A expression in a persistent AdV infection in 
lymphocytes (Chapter 2).  
1.5 Overarching Hypothesis 
The overall aim of this work is to identify chromatin modifiers and transcriptional 
regulators, known to play a role in repression of AdV gene expression in lytic infection or from 
vectors, that may contribute to the transcriptional repression needed to establish a persistent 
infection in lymphocytes. Specifically, I hypothesized that Class I, II HDACs, sirtuins, and CtBPs 
all play a role in transcriptional repression of persistent infection. I further hypothesized that this 
regulation, based on the NAD+ dependence of sirtuins and CtBPs, is inextricably linked to the 
dramatic shifts in metabolic state of resting and activated lymphocytes (depicted in Figure 1-7). 
Chapter 2 of this work describes experiments done to establish the link between metabolism and 
viral gene expression in persistently-infected lymphocytes, and the role of CtBP in repression of 
viral genes. Chapter 3 examines the roles that Class I, II HDACs and sirtuins play in repression of 
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specific viral genes. Chapter 4 describes additional work to address some technological challenges 
to the study of persistent AdV infection. Chapter 5 summarizes major findings and identifies 
remaining questions for further study. 
 
 
Figure 1-7. Overarching Hypothesis 
AdV DNA (shown in purple) enters the nucleus with protein VII (shown in blue).  The 
viral chromatin is remodeled by cellular histones and subject to transcriptional regulatory 
machinery in the cell. Repression of the viral chromatin, through interaction with cellular proteins 
dependent on the concentration of metabolic cofactors, is linked to the metabolic state of the 
lymphocyte. Modified from (139). 
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2 NAD-LINKED MECHANISMS OF GENE DE-REPRESSION AND A NOVEL ROLE 
FOR CTBP IN PERSISTENT ADENOVIRUS INFECTION OF LYMPHOCYTES 
This article was accepted for publication in Virology Journal on 11/26/2019.  
2.1 Abstract 
Background: Adenovirus (AdV) infection is ubiquitous in the human population and 
causes acute infection in the respiratory and gastrointestinal tract. In addition to lytic infections in 
epithelial cells, AdV can persist in a latent form in mucosal lymphocytes, and nearly 80% of 
children contain viral DNA in the lymphocytes of their tonsils and adenoids. Reactivation of latent 
AdV is thought to be the source of deadly viremia in pediatric transplant patients. Adenovirus 
latency and reactivation in lymphocytes is not well studied, though immune cell activation has 
been reported to promote productive infection from latency. Lymphocyte activation induces global 
changes in cellular gene expression along with robust changes in metabolic state. The ratio of free 
cytosolic NAD+/NADH can impact gene expression via modulation of transcriptional repressor 
complexes. The NAD-dependent transcriptional co-repressor C-terminal Binding Protein (CtBP) 
was discovered 25 years ago due to its high affinity binding to AdV E1A proteins, however, the 
role of this interaction in the viral life cycle remains unclear.  
Methods: The dynamics of persistently- and lytically-infected cells are evaluated. RT-
qPCR is used to evaluate AdV gene expression following lymphocyte activation, treatment with 
nicotinamide, or disruption of CtBP-E1A binding.  
Results: PMA and ionomycin stimulation shifts the NAD+/NADH ratio in lymphocytic 
cell lines and upregulates viral gene expression. Direct modulation of NAD+/NADH by 
nicotinamide treatment also upregulates early and late viral transcripts in persistently-infected 
cells. We found differential expression of the NAD-dependent CtBP protein homologs between 
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lymphocytes and epithelial cells, and inhibition of CtBP complexes upregulates AdV E1A 
expression in T lymphocyte cell lines but not in lytically-infected epithelial cells.  
Conclusions: Our data provide novel insight into factors that can regulate AdV infections 
in activated human lymphocytes and reveal that modulation of cellular NAD+/NADH can de-
repress adenovirus gene expression in persistently-infected lymphocytes. In contrast, disrupting 
the NAD-dependent CtBP repressor complex interaction with PxDLS-containing binding partners 
paradoxically alters AdV gene expression. Our findings also indicate that CtBP activities on viral 
gene expression may be distinct from those occurring upon metabolic alterations in cellular 
NAD+/NADH ratios or those occurring after lymphocyte activation.  
 
2.2 Background 
Adenovirus infection is ubiquitous in the human population, and the species C subgroup 
(AdV-C1, 2, 5, and 6) is the most widespread of these viruses. Species C AdVs cause acute 
infection in the respiratory and gastrointestinal tract (1-4). In addition to causing lytic infections 
in epithelial cells, adenoviruses have the ability to persist in a non-lytic state in mucosal 
lymphocytes (2,5-11).  AdV-C infections occur predominantly in the very young, and 
consequently nearly 80% of children contain viral DNA in the lymphocytes of their tonsils and 
adenoids (1-4). These infections can be life-threatening for immunocompromised pediatric 
transplant patients, and those receiving allogeneic hematopoietic stem cell transplants (allo-HSCT) 
are at significant risk for developing disseminated adenovirus disease. Although these infections 
and resulting disease can be initiated through de novo exposure to the virus, the predominant cause 
in severely immunocompromised patients is endogenous reactivation of AdV-C, types 1, 2, and 5 
(3).  The AdV-related post-transplantation mortality for these patients is estimated to be between 
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3.2 and 6.0%, potentially affecting more than 100 children per year in the U.S. (3,12,13). There is 
currently no medical intervention to protect against AdV reactivation, or FDA-approved treatment 
for AdV disease, and the mechanisms that allow the virus to persist and induce reactivation are 
almost entirely unknown (14,15).  
     Persistent AdV infections last for long periods of time following resolution of the initial 
lytic infection, and the virus can be intermittently detected in fecal samples for months to years 
after symptoms have abated (16).  Persistent infections in lymphocytes have been reported to 
exhibit a range of repressed states, from truly latent (with no production of infectious particles) to 
a “smoldering” infection with low viral yield (2,8).  Immunoactivation of tonsillar lymphocytes 
has been shown to reactivate latent AdV, but the cell-type specific mechanisms behind this de-
repression have not been studied (2).  B and T lymphocytic cell line models of persistent infection 
have been established that exhibit long-term persistent AdV infections marked by retention of high 
levels of viral genomes and very low viral protein expression (17,18). Interestingly, the persistent 
phase in these models has been shown to be regulated, in part, by transcriptional controls not seen 
in lytic infections. Several viral genes have been reported to display alternative patterns of 
expression when compared to lytic infections, suggesting specific programs of repression are 
present in persistent infections of lymphocytes (19-21).  
     As B and T lymphocytes transition from a resting to an activated state, they undergo 
dramatic shifts in gene expression and metabolism to accommodate robust proliferation and 
differentiation into effector cells. Programs of gene expression during both resting and activated 
states have been shown to be regulated in part by chromatin remodelers and co-repressors, 
including DNA methyltransferases (DNMTs), Class I and II histone deacetylases (HDACs), Class 
III HDACs (sirtuins), ten-eleven translocation (TET) family proteins,  and the C-terminal Binding 
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Protein family (22). Because the adenovirus genome is chromatinized through rapid association 
with cellular histones upon entry into the host cell nucleus, viral gene expression is likely regulated 
by these cellular chromatin-modifying mechanisms and responsive to immunoactivation of the 
host lymphocyte (23-25).  
     The C-terminal Binding Protein (CtBP) family of transcriptional corepressors was 
discovered through their high affinity binding to AdV E1A proteins (26,27). Mammalian cells 
express both CtBP1 and its homolog CtBP2 (collectively known as CtBP), which both share a 2D-
hydroxyacid dehydrogenase domain, RRT-binding domain, and the PxDLS-binding domain 
responsible for the interaction with E1A (reviewed in (28)).  CtBP homo- and hetero-dimers also 
likely form tetramers with the capacity to recruit many different chromatin modulators including 
Class I and II HDACs, histone methyltransferases, E3 ligases and other transcriptional regulators 
into large transcriptionally repressive complexes at the promoters of genes (28-31). The assembly 
and stability of these complexes are dependent on nicotinamide adenine dinucleotide (NAD+ and 
its reduced form NADH) binding, and CtBP has been reported to function as an NAD(H) sensor 
and therefore a link between metabolic state and transcriptional regulation (30,32-36).   
     Much has been reported about CtBP and its interaction with the viral E1A proteins. 
Initiation of the lytic AdV infection is marked by expression of the immediate early gene E1A, 
which has two main protein isoforms - large (13S E1A, 289R) and small (12S E1A, 243R) - 
responsible for transactivating other viral early genes and driving expression of cellular S-phase 
genes, respectively (37).  Both E1A isoforms interact with high affinity with both CtBP1 and 
CtBP2 through a PLDLS-motif located in the shared conserved region 4 (CR4) at the C-terminal 
end of the E1A proteins.  Large E1A has an additional CtBP interaction domain located in the CR3 
region unique to this isoform (38). Of note, NADH was found to facilitate binding of CtBP to E1A 
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at 1000-fold lower concentration than NAD+, suggesting that the NAD+/NADH ratio in the cell 
may affect the formation of CtBP-E1A protein complexes (32).   
    The role of the CtBP-E1A interaction in the lytic AdV life cycle is complex and has been 
reported to be either repressive or faciliatory, depending on the context. Mutation of the CtBP-
binding site in CR4 of E1A drastically reduces virus replication, but stable knock-down of CtBP2 
increases viral yield (39,40). CtBP1 and CtBP2 suppress the ras-cooperative transformative 
activity of the E1A proteins, but are required for E1B-55K cooperative transformation (26,39,41-
43). At the level of transcriptional regulation, CtBP has been found to both repress and enhance 
E1A transactivation of viral and cellular genes (38,44).  In a reciprocal relationship, E1A can exert 
influence over CtBP function as well, such as by altering acetylation and repressor-complex 
composition (44) and enhancing nuclear localization (45,46). These findings suggest that the high 
affinity binding between the E1A proteins and the CtBP proteins could form different context-
specific complexes with finely-tuned functions.  Given the complex nature of CtBP function 
during lytic infections of epithelial cells, it seems plausible that the CtBP proteins function in yet 
a different capacity within the unique cellular backdrop of persistent infection in lymphocytes. 
     The present study focuses on the mechanisms of viral reactivation in lymphocytes 
infected with AdV-C and provides experimental evidence for metabolically-linked mechanisms 
that could contribute to viral reactivation following cell activation. We show that viral transcription 
in lymphocyte models of AdV persistence is repressed compared to lytically-infected cells, but 
that relative amounts across viral transcripts are similar between the two infection types. Our data 
reveal that activation of lymphocytes shifts the NAD+/NADH ratio and that viral transcription is 
linked to alterations in this ratio. We also report differential expression of the NAD-dependent 
CtBP protein homologs between lymphocytes and epithelial cells. Last, our data reveal that 
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inhibition of CtBP interaction with PxDLS-motif binding partners upregulates AdV E1A 
expression in T lymphocytes but not epithelial cells. Together, our results provide novel insight 
into metabolic factors that can regulate adenoviral reactivation in human lymphocytes. 
2.3 Materials and Methods 
Cell lines 
The human lung carcinoma cell line A549 was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). BJAB (EBV-negative Burkitt’s lymphoma, (47)) and Jurkat 
(T cell Acute Lymphoblastic Leukemia [ALL]) were also obtained from the ATCC. KE37 
(immature T cell ALL) cells were purchased from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Braunschweig, Germany). Me-180 (HPV-positive cervical carcinoma) and 
CaLu1 (lung carcinoma) were obtained from Linda R. Gooding (Emory University, Atlanta, GA). 
A549 cells were grown in Dulbecco’s modified Eagle medium (DMEM) with 4.5μg of glucose 
per ml, 10% fetal calf serum (FCS), and 10 mM glutamine. BJAB, Jurkat, and KE37 cells were 
grown in RPMI medium supplemented with 10% FCS and 10mM glutamine. Me-180 and CaLu1 
were grown in McCoy’s medium, 10% FCS, and 10mM glutamine. Cells were routinely evaluated 
to ensure the absence of mycoplasma and lymphocyte cell lines were authenticated by Genetica 
Cell Line Testing (Burlington, NC). 
 
Adenoviruses  
The AdVC-5 mutant virus strain Ad5dl309 is phenotypically wild-type in cell culture and 
was obtained from Tom Shenk (Princeton University, Princeton, NJ). Ad5dl309 lacks genes 
necessary for evading adaptive immune attack (E3 RIDα and RIDβ proteins as well as the 14,700-
molecular-weight protein (14.7K protein)) in infected hosts (48). 
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Infection of lymphocytes with adenovirus 
Infection of lymphocyte cell lines with adenovirus was performed as described previously 
(49) with minor modifications. Lymphocytes were collected and washed in serum-free (SF) RPMI 
medium, and cell density was adjusted to 107 cells per mL in SF-RPMI medium. Virus was added 
to the cell suspension at 50 PFU/cell, spun for 45 minutes at 1000 x g at 25°C, and resuspended 
by agitation. Cells were then incubated at 37°C for 1.5 hours with gently flicking every 30 minutes. 
The infected cells were washed three times with complete RPMI medium and then resuspended in 
complete RPMI medium at 5x105 cells per mL for culture. Cell concentration and viability were 
monitored throughout the infection. Replicates for experiments were obtained from independent 
infections.  
 
Stimulation of Immune Cell Activation 
Lymphocytes were treated for 24 hours with 81nM PMA + 1.35𝜇M Ionomycin (1X 
EZCellÔ Cell Stimulation Cocktail, BioVision, Milpitas, CA). Following Fc block treatment (BD 
Pharmingen, San Jose, CA), cells were stained with fluorophore-conjugated antibodies against 
CD69 (PE, Biolegend, clone FN50) and CD25 (FITC, BioLegend, clone BC96), or stained with 
isotype control, and assessed by flow cytometry using LSR Fortessa (Becton Dickinson) and 
FlowJo Software (Becton Dickinson).  
 
Drug treatments 
Drug treatment concentration and time of exposure were optimized for all cell lines. For 
lymphocytic and epithelial cell lines, cells were seeded at a density of 3 x 105 and 1 x 105 cells per 
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mL, respectively, in complete medium supplemented with treatment doses of drugs. Treatment 
drugs and doses tested include nicotinamide (NAM, Sigma-Aldrich, [2, 5, 10mM]) and NSC95397 
(CtBP inhibitor, Tocris, Bristol, UK, [0.5, 1, 5, 10, 20𝜇M]). Cell growth and viability were 
assessed by Trypan blue exclusion at 12 (NSC95397 only), 24, and 48 hours (see Appendices). 
Experiments utilized the following doses which maintained the viability indicated: NAM-10mM, 
>80% for 48 hours; NSC95397-10𝜇M for 24 hours, which maintained >40% viability in 
lymphocytes and >70% viability for epithelial cells. 
 
Reverse transcription and quantitative PCR analysis of viral and cellular mRNA levels 
RT-qPCR was performed as described previously with minor modifications (50). Briefly, 
total RNA was isolated from 1 x 106 cells using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA) 
with RNase-free DNase treatment (Qiagen). After spectrophotometric quantification, 200ng of 
RNA was reverse transcribed into cDNA in 20𝜇L reactions (Maxima First Strand cDNA Synthesis 
Kit, Thermo Fisher Scientific, Waltham, MA).  RT-enzyme negative controls were included for 
each reaction. Primers and probes were obtained from Integrated DNA Technologies (Coralville, 
IA), with sequences specified below. Each cDNA sample was run in duplicate qPCR reactions 
using the Maxima Probe/ROX qPCR Master Mix (Thermo Fisher Scientific) with cycling 
conditions as described.   
     For all experiments in which changes to viral gene transcription were assessed and 
expression of our housekeeping gene (eukaryotic translation initiation factor 1, [EIF1]) was 
unchanged by treatment, we quantified relative amounts of target (fold-change over untreated) as 
2$(∆'(,*+,-*,.$∆'(,/0*+,-*,.) = 2$∆∆'( as described in (51). In experiments using NSC95397, four 
different housekeeping genes (GAPDH, HPRT1, ACTB, and EIF1) were all negatively impacted 
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by treatment. Because our primer amplification efficiencies are similar, and cDNA was prepared 
using equal amounts of RNA for all treatments, we used 2$∆'(3 = 2$('(,*+,-*,.$'(,/0*+,-*,.) (51) for 
each gene separately, and present the down-regulated housekeeping gene for reference. This 
formula was also used for comparing relative amounts across different viral transcripts of untreated 
samples. We approximate the constant K = 1 (represents the ratio between the target gene and the 
housekeeping gene of the number of molecules present at threshold cycle given an initial number 
of molecules, defined in Equation 4 (51)). For this, 2$∆'(∗ =
2$('(,*-+5,*	5,0,$'(,78/9,:,,;<05	5,0,)	was used to yield an approximate relative amount of target 
compared to the housekeeping gene for each viral gene.   
 
Primers and Probes: 
E1A (Sense sequence, 5’- GTTAGATTATGTGGAGCASCCC-3’, anti-sense sequence, 
5’-CAGGCTCAGGTTCAGACAC -3’, probe sequence, 5’-6 FAM-
ATGAGGACCTGTGGCATGTTTGTCT-3IABkFQ-3’) 
 
E3GP19K (Sense sequence, 5’-TTTACTCACCCTTGCGTCAG-3’, anti-sense sequence, 
5’-GCAGCTTTTCATGTTCTGTGG-3’, probe sequence, 5’-6 FAM-
CTGGCTCCTTAAAATCCACCTTTTGGG-3IABkFQ-3’) 
 
TLP HEXON (Sense sequence, 5’-AAAGGCGTCTAACCAGTCAC-3’, anti-sense 
sequence, 5’-CCCGAGATGTGCATGTAAGAC-3’, probe sequence, 5’-6 FAM-
CGCTTTCCAAGATGGCTACCCCT-3IABkFQ-3’) 
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EIF1 (Sense sequence, 5’- GATATAATCCTCAGTGCCAGCA-3’, anti-sense sequence, 
5’-GTATCGTATGTCCGCTATCCAG-3’, probe sequence, 5’-6 FAM-
CTCCACTCTTTCGACCCCTTTGCT-3IABkFQ-3’) 
 
Quantitative real time PCR analysis of viral DNA levels 
Infected or uninfected control cells were washed in phosphate-buffered saline (PBS) and 5 
x 105  cells for each sample were lysed in 100μL of NP-40–Tween buffer containing proteinase K, 
as described in (5). Samples were tested by real-time PCR for a region of hexon gene that is 
conserved among species C adenovirus serotypes. Samples were run in duplicate for each 
independent experiment, with cycling conditions as described. Viral genome numbers were 
quantified by comparison to an Ad2 DNA standard curve and normalized relative to GAPDH 
expression to account for small differences in cell input (5).        
 
Immunoblots for protein detection 
Protein lysates were prepared using RIPA buffer (Sigma-Aldrich) with 
protease/phosphatase inhibitors (Cell Signaling Technologies), and protein concentrations were 
quantified using a BCA protein assay (Thermo Scientific).  Thirty ug of protein was separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5 to 12% 
polyacrylamide gels (Mini-PROTEAN TGX gels, BioRad, Hercules, CA). Proteins were 
transferred onto nitrocellulose membranes (Thermo Scientific) overnight at 30mV at 4°C. 
Following confirmation of protein transfer with Ponceau S staining (Aqua Solutions, Deer Park, 
TX), membranes were blocked at room temperature (RT) with 5% bovine serum albumin (BSA) 
for 1 hour, washed three times with Tris-Buffered-Saline with 1% Tween (TBST), and incubated 
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with primary antibodies on a rocker overnight at 4°C. Following three washes with TBST, 
membranes were incubated with secondary HRP-conjugated antibodies for 1 hour at RT. 
Membranes were washed three times with TBST, the HyGLO HRP chemiluminescent reagent 
(Denville, Quebec, CA) used as substrate, and signal detected using x-ray film (MTC Bio). 
Primary antibodies include CtBP1 (mouse, 612042, BD Transduction Lab, San Jose, CA), CtBP2 
(mouse, 612044, BD Transduction Lab), and b-actin (rabbit, D6A8, Cell Signaling, Danvers, MA). 
Secondary antibodies used were also from Cell Signaling: HRP-linked anti-rabbit IgG (7074) and 
HRP-linked anti-mouse IgG (7076S).       
 
Quantification of total cellular NAD+ and NADH concentrations 
NAD+ and NADH concentrations were determined using the bioluminescent NAD/NADH-
Glo Assay from Promega (Madison, WI). Cells were plated at a density of 1.5-3 x 104 cells per 
well in 250μL complete media on 96-well plates. For determining the effects of treatments on 
NAD+/NADH ratios, cells were left untreated or drugs added, and all cells were incubated for 
times specified in figures. Nanomolar concentrations of NAD+ and NADH were determined 
following manufacturer’s instructions by comparison to a standard curve consisting of dilutions of 
b-Nicotinamide adenine dinucleotide (N8285, Sigma).        
 
 
Statistical analysis 
     Experiments were repeated at least three times unless otherwise indicated. The 
experimental data were analyzed using a student’s t-test in GraphPad Prism software. P-values 
less than 0.05 were considered statistically significant.  Independent infections of lymphocytes 
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exhibit a high degree of variability in gene expression preventing the ability to average 
observations across infections, thus for some experiments we have shown the results of 
independent replicate experiments. 
 
2.4 Results 
2.4.1 Viral transcription in persistently-infected lymphocytes is repressed compared to 
lytically-infected cells but relative amounts across viral transcripts are similar 
Lymphocytic cell line models of infection harbor high levels of viral DNA for long periods 
of time, with very low amounts of detectable viral proteins (17,21). As these cell-line infections 
progress over time, viral genome levels decline from peak levels during the “acute phase” (1-30 
days post infection (dpi)) into the “persistent phase” (> 30 dpi).  The viral genome is retained 
during persistence for more than 100 dpi at 10-1000 copies per cell (17,18). To further characterize 
the persistent phase dynamics, we examined the variability in the viral genome load across several 
independent infections. Using qPCR, we quantified viral genome copy number during both the 
acute and persistent phases of two persistently-infected lymphocytic cell lines (BJAB and KE37) 
and compared those to acutely-infected lymphocytes as well as lytically-infected cells (Jurkat) 
(Figure 2-1A). Acutely-infected BJAB and KE37 were found to carry similar viral loads to 
lytically-infected Jurkat cells (1 x 108-1 x 1011 copies per 107 cells). These levels are similar to 
those previously detected in lytically-infected epithelial cells (1.2 x 1011-1.6 x 1011 copies per 107  
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Figure 2-1.Characterization of viral genome quantities and transcriptional repression in 
persistently-infected lymphocytes.  
A) Viral genome copy numbers determined by qPCR as previously described (5). BJAB, 
KE37, and Jurkat were infected with a MOI 50. Error bars show median value with range. Cell 
information: BJAB, persistently-infected (n=9) and acutely-infected (n=3); KE37, persistently-
infected (n=9) and acutely-infected (n=3); lytically-infected Jurkat (n=5). Persistently-infected 
lymphocytes were evaluated between 50 to 241 dpi, lytically-infected Jurkat cells were evaluated 
at 2 to 4 dpi.  B) Viral transcription in persistently-infected lymphocytes was determined by RT-
qPCR and relative amounts of mRNA calculated as described in Materials and Methods and 
normalized to the housekeeping gene EIF1 (which was not affected by infection, and was set to 
1). The negative reciprocal was taken for values less than one to show down-regulation on the 
same scale.  C & D) Relative amounts of viral transcripts E1A-13S, E3gp19K, and hexon in 
persistently-infected (C) and lytically-infected cells (D) were determined by RT-qPCR using equal 
amounts of RNA. Relative amounts were calculated as described in Material and Methods and 
then normalized to E1A (which was set to 1). Experiments repeated at least 3 times with similar 
results. BJAB (n=4, 53-60 dpi), KE37 (n=4, 5-82 dpi), Jurkat (n=3, 2-4 dpi), A549 (n=3, 1-2 dpi).   
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cells 48 h post-infection with MOI 30) (49).  On average, persistently-infected cells harbor fewer 
copies of the viral genome than acutely-infected counterparts, though the differences are not 
significant (Figure 2-1A). Notably, lymphocyte infections are capable of maintaining 2 to 4-log 
differences in quantities of viral DNA infection-to-infection (1 x 105-1 x 109 copies per 107 cells).  
This variability in viral genome copy number has also been reported for naturally-infected mucosal 
lymphocytes which can range from 1 x 102 to 1 x 107 copies per 107 cells (2,8).   
We have previously reported that expression of the adenovirus death protein (ADP) is 
repressed in persistently-infected lymphocyte cell lines (21). Krzywkowski et al. (2017) also 
showed reduced E1A and MLP mRNA levels in persistently-infected BJAB cells, relative to 
lytically-infected HeLa cells even when viral DNA levels were comparably high (19). To extend 
these observations to other viral genes we quantified transcription from three genes expressed 
during immediate early (E1A), early (E3), and late (hexon) adenovirus infection. Quantities of viral 
transcripts from persistently-infected BJAB and KE37 cells were determined relative to a cellular 
housekeeping gene EIF1 (which was not altered by infection, data not shown). We compared 
persistent quantities to viral transcripts in lytically-infected Jurkat and A549 cells. In lytically-
infected cells, all viral transcripts were expressed at levels higher than the cellular reference gene 
(Figure 2-1B). Interestingly, viral transcription was markedly lower in lytically-infected Jurkat 
compared to A549, which may contribute to the delayed lysis reported for this infection (17). As 
expected, persistently-infected cells showed severely repressed levels of viral transcripts compared 
to lytically-infected cells, suggesting that for a substantial proportion of viral genomes infecting 
these cells, transcription is repressed.  
While viral gene expression was repressed in persistent infection, we sought to determine 
if viral expression of these same three genes (E1A, E3, and hexon) was maintained at expected 
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amounts relative to one another.  During the course of lytic infections in epithelial cells, the viral 
gene expression program follows a well-described progression (52-54). When maximum rates of 
transcription are evaluated, E1A mRNA is present in infected cells in lower amounts than that of 
E3.  Hexon mRNA and other late mRNA quantities are much larger than those of early genes (54-
56). To directly determine if viral transcript ratios seen in lytic infection were similar in persistent 
infection, we quantified relative viral transcription in persistently-infected BJAB and KE37 cells 
and compared them to relative transcript amounts in lytically-infected A549 and Jurkat cells. The 
fold change of both E3gp19K and hexon mRNA relative to E1A mRNA levels are shown in 
Figures 2-1C and 2-1D.  On average, E3 was 10-fold greater than E1A while hexon was 30-fold 
greater than E1A.  Moreover, despite the variability in genome copy number across samples 
(Figure 2-1A), relative quantities of E1A, E3gp19K, and hexon mRNA in persistently-infected 
cells (Figure 2-1C) are not distinguishably different from ratios in lytically-infected cells (Figure 
2-1D), indicating that persistently-infected cells expressing these genes are producing them at 
expected ratios.   
2.4.2 Cellular activation of infected lymphocyte cell lines upregulates viral gene 
expression 
Immune cell activation with a cocktail of activating agents (PMA, Ionomycin, IL-2, anti-
CD3 and anti-CD28) has previously been shown to reactivate viral transcription and induce 
production of infectious particles in latently-infected tonsillar lymphocytes (2). To determine if 
our infected cell line models would respond similarly, we first confirmed that immune cell 
signaling in our lymphocytic cell lines was functional.  Cells were activated with PMA/Iono for 
24 hours and the surface expression of CD25 and CD69, markers of lymphocyte activation, was 
measured by flow cytometry (57). Stimulation induced upregulation of both CD25 and CD69 
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compared to basal levels in all three cell lines (Figure 2-2A). We next evaluated viral E1A, E3, 
and hexon expression levels after cell activation. Stimulation upregulated viral gene expression in 
all three lymphocyte lines compared to untreated cells. Upregulation was most robust in the BJAB 
cells (~4-fold, 5-fold, and 3-fold for E1A, E3, and hexon, respectively) and small but detectable in 
E1A in the KE37 cells (1.2-fold average increase, Figure 2-2B). Of note, E1A responded in all 3 
replicates of infected KE37 while E3 was increased in 2 of 3 experiments. Overall, the viral early 
genes were more responsive to stimulation with PMA/Iono than the late gene hexon. In this regard, 
a PMA-responsive element has previously been reported in the E1A promoter (58). Further, PMA 
has been reported to act synergistically with E1A protein to upregulate E3 expression (59). Thus, 
these two actions of PMA at these early genes may contribute to the increases in viral early gene 
expression detected here in response to stimulation. Interestingly, PMA/Iono was also able to 
upregulate viral early gene expression in lytically-infected Jurkat cells at a level intermediate 
between the persistently infected BJAB and KE37 cell lines. 
2.4.3 Infection with adenovirus can reduce the NAD+/NADH ratio and 
PMA/ionomycin stimulation shifts this ratio in lymphocytic cell lines  
Lymphocytes remain in a resting state until activated and can undergo dramatic shifts in 
transcriptional programs upon activation (60-62), as well as shifts in metabolism resulting in 
significant increases in NAD+ and NADH concentrations (63).  These changes can impact 
transcription via chromatin remodelers dependent upon specific concentrations of metabolites as 
co-substrates or co-factors (64). To begin to understand some of the cellular mechanisms behind 
the PMA/Iono-induced upregulation of viral gene expression in infected lymphocytes, we first 
measured the impact of PMA/Iono stimulation upon cellular NAD+/NADH ratios in our 
lymphocytic cell lines. Treatment with PMA/Iono increased the NAD+/NADH ratio in our three  
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Figure 2-2.Cell stimulation with PMA and Ionomycin upregulates viral gene expression in 
infected lymphocytic cell lines. 
A) Infected BJAB, KE37, and Jurkat cells were stimulated with PMA/Iono for 24 hours 
and stained with monoclonal antibodies for CD25 (FITC-labeled) and CD69 (PE-labeled) detected 
by flow cytometry. Percentages indicate number of cells positive for the indicated marker 
following stimulation.  Shaded area and open area show untreated and PMA/Iono-treated samples, 
respectively. B) PMA/Iono-induced changes to viral gene expression were evaluated in 
persistently-infected BJAB or KE37 cells (between 50 to 100 dpi) and lytically-infected Jurkat 
cells (2 dpi).  Cells were treated for 24 hours with PMA/Iono and changes to viral gene expression 
assessed by RT-qPCR. Lytically-infected Jurkat are demarked by the shaded region to differentiate 
from persistently-infected cells. Four infected BJAB, three infected KE37, and two infected Jurkat 
replicate infections are shown. Fold change is shown over untreated samples (set to 1). Dashed 
gray line shows the line of fold change = 1. Error bars show standard deviation in replicate wells. 
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lymphocyte cell lines, with a significant 3.3-fold increase in BJAB (P=0.0006) and a 1.9-fold 
increase in Jurkat (P=0.0465) (Figure 2-3A). KE37 had the highest average NAD+/NADH ratio 
when untreated.  This cell line also had the widest range of NAD+/NADH-ratio values in an 
unstimulated state, and though we observed an increase in ratio for KE37 after PMA/Iono 
treatment, it was not statistically significant. This cell line also exhibited the smallest increase in 
viral gene expression by PMA/Iono (Figure 2-2B).   
 
 
Figure 2-3. PMA and ionomycin treatment increases NAD+/NADH ratio in lymphocyte cell 
lines.  
A) Uninfected cells were treated with PMA/Iono for 4 hours, and total cellular NAD+ and 
NADH nM concentrations were determined using a bioluminescent assay with standard curve. 
Numbers of replicates: BJAB - untreated, n = 8, treated, n = 3; Jurkat – untreated, n = 8, treated, n 
= 3; KE37 – untreated, n = 5, treated, n = 3. Fold-increase in treated over untreated is shown in 
bold in the gray bar (mean of the treated/mean of the untreated). Error bars show standard 
deviations of the NAD+/NADH ratios. P-values were determined using a student’s t-test. B) Impact 
of persistent infection on NAD+/NADH ratios.  Total nM NAD+ and NADH were determined in 
persistently infected lymphocytes (>50 dpi) as described in Material and Methods. For all samples, 
n = 5. Mean and standard deviation of the ratios is shown. P-values were calculated using student’s 
t-test.   
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In the course of lytic infection of epithelial cells, AdV is known to alter metabolic pathways 
of the host cell, such as glycolysis and the tricarboxylic acid (TCA) cycle, to generate the 
metabolites and macromolecular precursors demanded by viral replication (reviewed in (65)). 
Whether persistent adenovirus infection results in metabolic reprogramming of the host cell is not 
known, although persistently-infected cells continue to divide normally as one measure of cellular 
activity (17). If viral gene expression is linked to the NAD+/NADH ratio of the cell, and treatments 
which increase the NAD+/NADH ratio increase viral gene expression (Figure 2-2B & 2-3A), we 
wondered if the NAD+/NADH ratio was reduced in persistently-infected cells where viral gene 
expression is repressed. To address this question, we measured the NAD+/NADH ratio in 
persistently-infected BJAB and KE37 cells compared with their uninfected counterparts (Figure 
2-3B). On average, the NAD+/NADH ratio is reduced in persistently-infected lymphocytes 
compared to uninfected controls and approaches significance in KE37 cells (P=0.0817). BJAB 
cells, however, have a much lower baseline ratio as compared to KE37 (1.4 vs 6, respectively), 
and infection appears to moderately reduce it further, though not to statistically significantly levels.  
 
 
2.4.4 Direct modulation of the NAD+/NADH ratio can upregulate viral gene 
expression in persistently-infected cells  
To more directly evaluate the impact that shifts in the NAD+/NADH ratio could have on 
viral gene expression, we treated cells with nicotinamide (NAM) which has been reported to 
increase the NAD+/NADH ratio (66).  As expected, NAM treatment increased the NAD+/NADH 
ratio in BJAB (1.3 fold) and more significantly altered KE37 (2.9-fold; P=0.0294). Again, Jurkat 
fell in between these 2 cell lines with a 1.9-fold increase (P=0.0706, data not shown).  Following 
NAM treatment of persistently-infected lymphocytes, we measured the impact of increasing the 
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NAD+/NADH on viral gene expression. As shown in Figure 2-4B, treatment with NAM increased 
viral gene expression of early and late genes in both persistently-infected cell lines. E1A and E3 
expression appeared to be more robustly increased in KE37 as compared to infected BJAB cells. 
Moreover, these NAM-induced increases in viral gene transcription could be seen at the protein 
level by flow cytometry during the acute phase of infection when viral proteins are expressed at 
detectable levels, and both BJAB cells and KE37 cells exhibited increased expression of hexon 
protein following treatment with NAM at 20 dpi (data not shown). Interestingly, the increases in 
viral gene expression detected, following treatment with either PMA/Iono and NAM, appear to 
correspond to the increases detected in NAD+/NADH ratio. In KE37, NAM shifted the 
NAD+/NADH ratio 2.9-fold (Figure 2-4A) compared to 1.4-fold with PMA/Iono (Figure 2-3A). 
NAM similarly increased viral mRNA more robustly (> 2-fold for all 3 viral genes) (Figure 2-4B) 
than did PMA/Iono treatment (< 1.5-fold for E1A only) (Figure 2-2B). In BJAB cells, PMA/Iono 
induced a larger shift in the NAD+/NADH ratio than did NAM (3.3-fold compared to 1.3-fold, 
respectively). PMA/Iono also induced larger increases in viral gene expression (Figure 2-2B) than 
NAM (Figure 2-4B) (> 3-fold compared to < 3-fold). These results suggest that viral gene 
expression in lymphocytes could be tied to the NAD+/NADH ratio of the host cell. 
 
2.4.5 Differential expression of CtBP homologs between lymphocytes and epithelial 
cells  
The AdV genome remains episomal in lymphocytes (17) and associates with cellular 
histones in infected cells (24,25,33).  CtBP repressor complexes associate with histones to regulate 
gene expression and are sensitive to NAD+/NADH levels (35). Moreover, these proteins were  
 
53 
 
Figure 2-4. Viral gene expression is responsive to the NAD+/NADH ratio. 
A) Uninfected cells were treated with 10mM NAM for 24 hours, and total cellular NAD+ 
and NADH concentrations determined as described previously. N = 3 for all cell lines. Fold-
increase in treated over untreated is shown in bold in the gray bar (mean of the treated/mean of the 
untreated). Error bars show standard deviations of the NAD+/NADH ratios. P-values were 
determined using a student’s t-test. B) Impact of NAM on viral gene expression in persistently-
infected cells. Persistently-infected BJAB and KE37 (>50 dpi) were treated with 10mM NAM for 
24 hours. Following RT-qPCR, fold-change in viral is calculated using 2$∆∆'= as described in the 
Material and Methods, with untreated sample as reference (set to 1) and cellular gene EIF1 as the 
housekeeping gene. Dashed gray line shows fold change = 1. Error bars show standard deviation 
in replicate wells. One representative experiment for each cell line is shown. This experiment was 
repeated three times with similar results using BJAB cells.  This experiment was repeated four 
times for hexon in KE37 cells with similar results and twice for E1A and E3 with similar results.  
 
discovred more than two decades ago through their high affinity interactions with AdV E1A 
proteins (289R and 243R, large and small E1A respectively) (26,27).  E1A large and small proteins 
are the first to be expressed upon infection and are critical for auto-activating the E1A gene, 
transactivating expression of other early viral genes, and driving the cell into S-phase (67). Thus, 
these proteins must be tightly controlled in cells where persistence, and not lysis, is the outcome.  
CtBP has paradoxically been reported to both repress and potentiate AdV infections during lytic 
infection of epithelial cells (26,38,39,41-44). We thus wanted to investigate if the CtBP proteins 
could be involved in the repression of viral transcription during persistent infection in 
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lymphocytes. Although CtBP1 and CtBP2 share a high degree of homology, differences in 
expression patterns, structure, and localization suggest context-dependent functions of these co-
repressors.  To begin understanding if these proteins could be contributing to AdV gene repression 
we first evaluated the CtBP protein levels in our cells and discovered striking differences between 
lymphocytic and epithelial cell lines. We found that CtBP2 was undetectable in all lymphocyte 
cell lines compared to the lung epithelial cell line A549 (Figure 2-5A). To determine if the high 
level of CtBP2 expression was a characteristic of other AdV-permissive epithelial cell lines, we 
evaluated two additional epithelial cell lines, Me-180 (cervical) and CaLu-1 (lung) (68,69) (Figure 
2-5B). We detected similarly abundant amounts of CtBP2 in these epithelial cells. CtBP1 
expression was consistent across the cell lines, with the exception of A549 cells which had the 
lowest amount of CtBP1 protein among all the cell lines. Because persistent infection has been 
shown to alter expression of some cellular proteins in lymphocytes (17), we confirmed that CtBP1 
was expressed at similar levels in both uninfected and persistently-infected lymphocytic cell lines 
(Figure 2-5C). Persistent infection also did not alter CtBP2 protein levels in lymphocytes and 
remained undetectable (Figure 2-5C). The striking difference in the CtBP expression profiles 
between epithelial cells and lymphocytes suggests that CtBP could be impacting adenovirus 
infection differently in lymphocytes as compared to what has been previously reported in epithelial 
cells (44-46). 
 
2.4.6 Inhibition of CtBP-E1A interaction upregulates E1A 13S expression in T 
lymphocyte cell lines  
To examine the role CtBP might have on viral transcription in lymphocytes, we utilized 
the small molecule inhibitor NSC95397. This compound specifically blocks binding between 
CtBP and PxDLS-containing partners and has been shown to disrupt the CtBP1-E1A interaction  
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Figure 2-5. Epithelial cells and lymphocytic cells differ in CtBP2 expression. 
Western blot analysis of CtBP1 and CtBP2 proteins was performed on epithelial and 
lymphocytic cells as described in the Material and Methods.  Permissive epithelial cells lines A549 
(lung), Me-180 (cervical) and CaLu-1 (lung) are shown. b-actin protein levels were used as a 
control for equal protein loading.  
 
 
(70). First, we confirmed that treatment with NSC95397 did not alter CtBP1 protein levels in 
persistently-infected lymphocytes (Figure 2-6A), and CtBP2 likewise remained undetectable (data 
not shown).  We next examined the effect of NSC95397 treatment on viral gene expression in 
persistently-infected lymphocytic cell lines. Treatment of BJAB cells with NSC95397 caused 
down-regulation of all viral genes across three independent experiments (Figure 2-6B), however, 
E1A expression was the least impacted.  E1A mRNA decreased 1.5- to 3-fold compared to the 
larger decrease in hexon (4- to 30-fold). Surprisingly, NSC95397 induced a more robust down-
regulation of the cellular housekeeping gene EIF1 (2-, 4- and 16-fold). We tested 3 additional 
housekeeping genes (glyceraldehyde-3-phosphate dehydrogenase [GAPDH], hypoxanthine 
phosphoribosyltransferase 1 [HPRT1], and b-actin [ACTB]) across all lymphocyte lines and saw 
robust down-regulation of each of them ranging from 2- to 11-fold (data not shown).  Interestingly, 
the down-regulation of the housekeeping gene in BJAB cells was greater than the down-regulation 
observed for E1A. Because of the robust down-regulation of multiple housekeeping genes tested  
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Figure 2-6. CtBP-binding inhibitor, NSC95397, differentially impacts AdV gene 
expression across lymphocytic and epithelial cell lines. 
A) Western blot analysis of CtBP1 protein was performed as described in Materials and Methods 
on cell lysates collected with or without 24-hour treatment with NSC95397. Both persistently-
infected KE37 and BJAB were 66 dpi.  B-E) RT-qPCR and analysis to assess viral gene expression 
performed as described for NSC95397 treatment in Material and Methods. B) Persistently-infected 
BJAB (≥61 dpi, n = 3), C) persistently-infected KE37 (≥80 dpi, n = 3), D) lytically-infected Jurkat 
(2 dpi, n = 3). Down-regulated values are shown as the negative reciprocal, which eliminates 
values falling between -1 and 1 (indicated by shaded zone). Error bars show standard deviation on 
replicate wells.  E) Lytically-infected epithelial cells A549 (2 dpi, error bars represent the SD of 3 
independent experiments), CaLu1 (2 dpi, n =1, SD of replicate wells), and Me-180 (2 dpi, n = 1, 
SD of replicate wells).  F) Comparison of average change in E1A expression induced by 
NSC95397 treatment in T cell lines (KE37 and Jurkat, data shown in Figures 6C and 6D) and 
epithelial cells (data shown in Figure 6E). Shaded zone between -1 and 1 as described above. 
Error bars show SD of fold-change values.  P-value was determined using student’s t-test. 
In
f K
E3
7
In
f K
E3
7 
+ 
N
SC
In
f B
JA
B
In
f B
JA
B 
+ 
N
SC
CtBP1
!-actin
A
iBJ
AB
-1
iBJ
AB
-2
iBJ
AB
-3
-30
-25
-15
-10
-5
0
5
Fo
ld
 C
ha
ng
e 
(2
^-
Δ
Ct
)
BJAB
E1A 13S
E3gp19K
Hexon
EIF1
B
iKE
37
-1
iKE
37
-2
iKE
37
-3
-100
-80
-25
-20
-15
-10
-5
0
5
Fo
ld
 C
ha
ng
e 
(2
^-
Δ
Ct
)
KE37
E1A 13S
E3gp19K
Hexon
EIF1
iJu
rka
t-1
iJu
rka
t-2
iJu
rka
t-3
-20
-15
-10
-5
0
5
Fo
ld
 C
ha
ng
e 
(2
^-
Δ
Ct
)
Jurkat
E1A 13S
E3gp19K
Hexon
EIF1
C D 
A549 CaLu1 Me-180
-20
-15
-10
-5
0
5
Fo
ld
 C
ha
ng
e 
(2
^-
Δ
Ct
)
Epithelial Cells
E1A 13S
E3gp19K
Hexon
EIF1
E
T c
ell
s (
KE
37
, J
ur
ka
t)
Ep
ith
eli
al 
Ce
lls
-2
0
2
4
6
Fo
ld
 C
ha
ng
e 
(2
^-
Δ
Ct
)
p=0.0012
T c
ell
s 
(K
E3
7, 
Ju
rka
t)
Ep
ith
eli
al 
Ce
lls
F
57 
 
in our study, fold-changes in gene expression between treated and untreated cells are shown 
without normalization to an endogenous control as described in Material and Methods (51).  
     Inhibition of CtBP binding with PxDLS-containing partners using NSC95397 also 
caused decreases in hexon mRNA in both KE37 cells (2- to 20-fold) and Jurkat cells (5- to 10-
fold) (Figure 2-6C & 2-6D). CtBP inhibition, however, has a noticeably different effect on E1A 
expression in both of these T cell lines where E1A is upregulated by 1.5- to 4-fold. The expression 
of E3 was minimally impacted in these cells.  These data suggest that CtBP binding with PxDLS-
containing partners may be repressing transcription of E1A in T cells and that inhibiting this 
binding allows for expression. In contrast, CtBP may paradoxically be necessary for expression of 
the viral late gene hexon in lymphocytes, since it was maximally downregulated by NSC95397 
treatment in both the B and T cell lines.   
     All of the lymphocyte cell lines have delayed infection dynamics as compared to 
infected epithelial cells (49).  In addition, though Jurkat cells undergo a lytic infection with AdV-
C5, they still exhibit much reduced levels of viral gene expression (Figure 2-1B). To find out if 
inhibiting CtBP binding with PxDLS-containing partners would have the same effect on viral 
transcription in epithelial cells, we initiated treatment with NSC95397 in lytically-infected 
epithelial cells. As shown in Figure 2-6E, NSC95397 treatment had almost no impact on viral gene 
expression in A549 cells. Because the lytic life cycle in A549 is rapid and usually complete by 48 
hours, we also assessed viral gene expression at 6 hours post-infection (5 hours after the addition 
of NSC95397). No effect of NSC95397 treatment could be seen at this earlier time point in 
infection (data not shown).  Interestingly, when we assessed viral transcription in two other 
epithelial cell lines, CaLu1 and Me-180, NSC95397 treatment negatively impacted hexon 
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expression, though not nearly to the level observed in lymphocytes, causing 3- to 4-fold down-
regulation (Figure 2-6E). As with A549 cells, NSC95397 treatment did not induce any 
upregulation of E1A in these cells, and there was a negligible impact on the expression of the 
housekeeping gene. The significant difference in impact of NSC95397 treatment on E1A 
expression between T cell lines and epithelial cell lines (P=0.0012) is shown in Figure 2-6F. 
Overall, NSC95397 treatment strongly impacted both cellular and viral gene expression in infected 
lymphocytes (both persistently- and lytically-infected) but had much less impact on infected 
epithelial cells. Further, the unique gene expression changes do not appear to be wholly related to 
the cell sensitivity to NSC95397 toxicity as ME-180 cells displayed sensitivity similar to the 
lymphocytic cell lines (data not shown). 
2.5 Discussion 
Most of what is known about adenovirus is from studies of lytically-infected cells, and 
adenovirus latency and reactivation are not well characterized. The virus can be life-threatening 
for immunocompromised individuals as well as pediatric transplant patients, however, the 
mechanisms that allow the virus to persist, or those that induce reactivation, are almost entirely 
unknown. Patient samples have shown that lymphocytes of the tonsils, adenoids (5), and 
gastrointestinal tract (8) contain AdV DNA and are presumably the sites of reactivation.  The lack 
of small-animal models of persistent adenovirus infection has been an obstacle to studying 
infection dynamics in vivo, but a study of AdV infection using humanized mice has recently shown 
that persistently-infected cells could also be found in the bone marrow (71).  
     Our previous studies of AdV-infected lymphocytes from tonsils or adenoids suggest 
that replicating virus is more common among younger donors, however, high genome copy 
number did not appear to correlate with active replication (2). Replicating virus could be detected 
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in cells containing a range of genome copy numbers, from as few as 104 to as many as 106 AdV 
genomes per 107 cells (2).  Our cell line models of persistent lymphocyte infection carry AdV 
DNA levels in a range between 1 x 105-1 x 109 copies per 107 cells (Figure 2-1A).  Within these 
persistently-infected models, many viral transcripts can be detected in low amounts with fewer 
than 1% of the cells expressing detectable levels of viral proteins or producing virus (20,21).   
     The persistent phase of infection has been shown to be regulated, in part, by 
transcriptional controls not seen in lytic infections. Murali et al. (2014) determined that the E3-
Adenovirus Death Protein (ADP) gene is repressed both transcriptionally and post-
transcriptionally in cells which harbor persistent AdV infection (21). Krzywkowski et al. (2017) 
showed that in persistently-infected BJAB, very few individual cells express E1A mRNA or Major 
Late Transcription Unit mRNA at levels comparable to lytically-infected HeLa cells, even when 
the cells harbored large amounts of viral DNA (19). In contrast, Furuse et al. (2013) determined 
that persistently-infected BJAB expressed amounts of VA RNAI and VA RNAII that were 
comparable to those expressed in lytic infections. However, the relative proportion of the two 
transcripts differed when compared to lytically infected cells (20).  In our current study, we report 
low expression of both early (E1A and E3) and late genes (hexon) in infected lymphocytes as 
compared to lytically-infected cells (Figure 2-1B). Indeed, the levels of viral transcripts are all 
relatively lower than the expression level of the representative housekeeping gene. In contrast, 
AdV transcript levels are relatively higher than housekeeping gene expression in both the lytically-
infected T cells (Jurkat) and lytically-infected epithelial cells (A549). However, we found reduced 
levels of viral transcripts in lytically-infected T cells as compared to lytically-infected epithelial 
cells revealing that lymphocytes in general have lower levels of AdV gene expression. We 
attempted to confirm differences in viral gene expression at the protein level but were unable to 
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detect viral proteins which are in low abundance during viral persistence (data not shown). Despite 
some degree of transcriptional repression in the lymphocytes, viral mRNA ratios were surprisingly 
similar between persistently-infected and lytically-infected cells (Figures 2-1C and 2-1D, 
respectively). These findings in lymphocytes are in line with amounts of E1A, E3, and hexon 
mRNAs (~4, 35, and 90%, respectively), quantified as a percent of GAPDH, at 36 hours post-
infection in normal lung fibroblasts recently reported by Crisostomo et al. (2019) (54). 
      Immunoactivation of tonsillar lymphocytes has been shown to reactivate latent AdV 
causing increases in viral gene expression and productive infection (2). In previous studies, a 
cocktail of immune cell stimulators was used including PMA, Ionomycin, IL-2, anti-CD3 and anti-
CD28, however, no specific mechanisms for viral gene de-repression were determined. In addition, 
these prior studies on activation of naturally infected lymphocytes were done using samples that 
contained both T cells and B cells together. In the current study, we report that PMA/Iono alone is 
sufficient to induce AdV gene expression in B and T cell models of persistent infection, as well as 
in lytically-infected Jurkat cells (Figure 2-2B). In addition, we found that the magnitude of change 
in viral expression mirrors the change observed in the NAD+/NADH ratio (Figure 2-3A). 
PMA/Iono treatment increased total cellular NAD+ and NADH concentrations (data not shown) 
and significantly increased the NAD+/NADH ratio in BJAB and Jurkat cells; large increases in 
AdV early gene expression were readily observable in these cells by 24 hours. Stimulation, 
including PMA/Iono treatment, of resting lymphocytes has been well-documented to shift the 
metabolic program from primarily oxidative phosphorylation to glycolysis, which increases lactate 
production, increases synthesis of biosynthetic intermediates, and shifts the NAD+/NADH ratio 
(63,79,80). Thus, our data support the notion that changes in the metabolic status of lymphocytes 
can promote reactivation of AdV gene expression.  In the current study, PMA/Iono had the least 
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impact on AdV gene expression in KE37 cells which corresponded with the non-significant change 
detected in the NAD+/NADH ratio in these cells after treatment. Whether the addition of other T 
cell stimulating agents (IL-2, anti-CD3 and anti-CD28) can induce a significant change in this 
ratio, as well as more robust changes in AdV gene expression, is still under investigation. 
     Interestingly, when comparing the basal NAD+/NADH ratios in the two persistently-
infected cell lines, KE37 and BJAB, a trend toward viral infection reducing the NAD+/NADH ratio 
relative to their uninfected counterparts could be seen, though significance was not reached (Figure 
2-3B). These samples were evaluated at different times post-infection, and it is intriguing to 
speculate that AdV may significantly impact the NAD+/NADH ratio of the cells it persistently 
infects at some point during the course of the infection.  How the virus would modulate cell 
metabolism mechanistically is unclear. Persistent adenovirus infection of B-lymphocytes has been 
shown to significantly down-regulate several cellular genes (BBS9, BNIP3, BTG3, CXADR, 
SLFN11, and SPARCL (50)), however, none are reported to obviously function in the regulation 
of metabolism. Nonetheless, it is possible that some of the other genes identified as altered by AdV 
infection could play a role in this effect ((50),  and supplemental data therein).   
    Nicotinamide (NAM), which is recycled by the cellular NAD+-salvage pathway and 
converted into NAD+, can be used to manipulate the NAD+/NADH ratio of cells (81). NAM 
treatment of persistently-infected cell lines significantly increased the NAD+/NADH ratio in KE37 
while a much smaller change was induced in BJAB cells (Figure 2-4A).  Nonetheless, increased 
viral gene expression could be detected in both cell lines (Figure 2-4B) suggesting that alterations 
in this metabolic ratio can induce viral gene expression in lymphocytes. Interestingly, in contrast 
to the robust PMA/Iono-induced upregulation of E1A and large increase in NAD+/NADH ratio 
seen in BJAB (3.3-fold, Figure 2-2B), there was no apparent change in E1A expression when the 
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ratio was only increased 1.3-fold with NAM (Figure 2-4B). A similar relationship is seen between 
E1A expression and the shift in the metabolic ratio in KE37, where more E1A expression is seen 
following larger increases in the NAD+/NADH ratio (Figures 2-4B, 2-2B).  These findings support 
a link between metabolic shifts in lymphocytes and the magnitude of AdV de-repression induced. 
       The link between the metabolic state of cells and gene expression contributes to 
lymphocyte functional responses following immune stimulation (64,82,83). This transcriptional 
regulation involves chromatin remodelers dependent upon specific concentrations of metabolites 
that serve as co-substrates or co-factors (64). CtBP is a well-known repressor of gene expression 
that was discovered through its interaction with E1A (26,27,84). CtBP tetramers associate with 
epigenetic enzymes forming complexes that modify the chromatin environment through 
coordinated histone modifications, allowing for the effective repression of genes targeted by DNA 
binding proteins associated with the complex (30-36,85-87). The stability of CtBP tetramers is 
dependent upon NAD(H) binding.  Because AdV gene expression in lymphocytes is responsive to 
shifts in the NAD+/NADH ratio, we investigated whether CtBP, as a reported metabolic sensor, 
could be contributing to the transcriptional repression evident in persistent infection. When 
comparing CtBP protein levels, we found that our three lymphocyte cell lines only expressed 
CtBP1 and that CtBP2 protein could not be detected (Figure 2-5A). CtBP2 expression has 
previously been reported to be in low abundance or undetectable in leukocytes, immune tissues, 
and lymphocyte cell lines (29). In contrast to the lymphocytes evaluated in our study, A549 cells 
expressed high levels of CtBP2 with lower levels of CtBP1 (Figure 2-5B). This finding suggested 
that the composition of CtBP complexes in lymphocytes is different than in epithelial cells, and 
therefore CtBP may interact differently with viral proteins in lymphocytes than what has been 
reported for epithelial cells.  
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     NSC95397 is a small-molecule inhibitor of CtBP which acts through the disruption of 
CtBP binding to PxDLS-containing partners, including E1A (70). Interestingly, treatment with 
NSC95397 resulted in mixed changes in expression of AdV genes (Figure 2-6,B-E).  E1A 
expression was increased in the T cells lines (KE37 and Jurkat) but minimally impacted in the B 
cell line (BJAB). In sharp contrast to E1A, hexon expression was consistently downregulated 
across all the lymphocyte cell lines. The ability of NSC95397 to impact E1A expression in both a 
lytically-infected T cell line as well as a persistently-infected T cell line could indicate a T 
lymphocyte specific role for the disrupted interaction.  Unlike the impact seen in T lymphocytes, 
none of the epithelial cell lines showed an increase in E1A expression with NSC95397 treatment 
(Figure 2-6E). Among the epithelial cell lines, A459 showed negligible changes in AdV expression 
following treatment with NSC95397 while Me-180 and CaLu exhibited moderate downregulation 
of both hexon and E3 (Figure 2-6E).  Whether this downregulation is attributable to the higher 
amount of CtBP1 present in these two epithelial cell lines as compared to A549 (Figure 2-5B) is 
still unclear.    
     Of note, cell viability, especially that of transformed cell lines, can be negatively 
impacted following treatment with NSC95397 (70). In our experiments, we optimized treatment 
timing to maintain cell viability at or above roughly 50% (data not shown). NSC95397 also 
induced substantial downregulation of multiple housekeeping genes (Figure 2-6,B-D, and 
unpublished data), although this effect did not directly relate to the viability of the cells.  For 
example, among the epithelial cell lines, Me-180 cells exhibited the highest reduction in viability 
with treatment (data not shown), however, the housekeeping gene remained unchanged. One 
limitation to our study is the inherent variability between individual infections of lymphocytes 
which does not allow for averaging of data across independent infections. Nonetheless, our 
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primary observations remain consistent between multiple infections, which are shown 
individually.  
 In addition to the use of the small-molecule inhibitor NSC95397, another potential 
experimental strategy for understanding the impact of CtBP1 on persistent infection in 
lymphocytes is transient knock-down of CtBP1 expression using shRNA or siRNA. Primary 
lymphocytes and lymphocytic cell lines are notoriously challenging to transfect using lipid-based 
approaches (88), but electroporation has been used successfully to deliver regulatory RNA with 
high efficiency (89).  In our current study, we attempted to transfect our persistently-infected 
lymphocytic cell lines with knock-down siRNA through electroporation and found that 
electroporation alone was sufficient to upregulate viral gene expression (data not shown).  Future 
attempts to use a CtBP1 knock-down approach may include stable transduction with an inducible 
shRNA expression vector prior to infection of the lymphocytes, which would allow controlled 
expression of the regulatory RNA and resulting CtBP1 knock-down only after the persistent phase 
of infection has been established. 
     CtBP gene regulation is complex with many paradoxical activities reported for its 
function. The differences in CtBP expression profile between our cell line models of lytic and 
persistent infection suggest that distinctions in known function, structure, and localization of the 
two CtBP homologs may be important for infection outcome in these cells. While CtBP1 is 
ubiquitously expressed, CtBP2 expression is more tissue and cell-type specific (29). Structurally, 
CtBP1 and CtBP2 differ slightly by a nuclear localization signal (NLS) only present in the N-
terminal of CtBP2 and a PDZ-binding domain only present in the C-terminal of CtBP1 (90). The 
NLS present, and a key p300 acetylation site on lysine 10 within the NLS, are responsible for the 
nuclear localization of CtBP2 (45). On the other hand, the localization of CtBP1, which is found 
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both in the cytoplasm and the nucleus, is subject to more complex regulation; sumoylation at lysine 
K428, in conjunction with the PDZ-binding domain regulate nuclear localization (90). CtBP1 can 
also be recruited to the nucleus by a CtBP2-dependent mechanism (91). Additionally, distribution 
of CtBP1 between the cytoplasm and the nucleus is also reported to be dependent upon the cell-
type, further implicating other factors in localization regulation (90-93).  How these reported 
differences in the complex regulation of CtBP impact the viral life cycle in these cells will require 
additional study.        
      This is the first investigation into a possible role for CtBP in persistent infection of 
lymphocytes, and we observed that NSC95397 treatment could release a CtBP-associated 
repression of E1A in infected T cell lines. Although the Jurkat infections are lytic and KE37 
infections persist for months, both show suppression of viral gene expression relative to epithelial 
cells (17). A549 cells produce high levels of viral late proteins within 24 hours of infection, while 
Jurkat and KE37 do not achieve peak levels until 1-3 or 3-7 dpi, respectively, despite equivalent 
amounts of viral DNA (Figure 2-1A and (17,21)). Transcription is also repressed in both cell lines 
relative to A549 (Figure 2-1B).  Whether these overall reduced levels of viral transcripts stem from 
a repressive mechanism at the E1A promoter remains to be determined, but it seems likely that 
repression of the master regulator of AdV infection, E1A, could have a profound influence on the 
infection dynamics. We were surprised to find that, under the same treatment conditions, we 
observed no de-repression of E1A in BJAB cells. It is possible that the binding partners 
incorporated into CtBP complexes between our B and T cell lines may be different, and 
additionally, may be influenced by the differences in basal NAD+/NADH ratios detected in our 
lymphocyte cell lines (35). These are all areas worthy of further investigation.  
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In one of the only other reports of a direct mechanism involved in establishment of 
persistent infection, Zheng et al. showed that repression of AdV transcription, resulting from 
interferon (IFN) a- and IFNg-induced recruitment of E2F/Rb complexes to the E1A enhancer, was 
able to induce persistent infection in primary and normal epithelial cells (72).  While IFN-treatment 
allowed epithelial cells to survive infection for long periods of time with reduced viral gene 
expression in this study, production of infectious virus could be detected at all time points (72). 
Notably, upon cessation of IFN-treatment, viral replication rebounded dramatically (72).  In 
contrast, in both naturally-infected lymphocytes extracted from tonsil and adenoid tissue and in 
lymphocyte cell lines, viral transcription is similarly repressed but infectious virus can be detected 
only in rare instances (2,17). This suggests that, even without chronic IFN exposure, a more 
extensive repression of viral gene expression has occurred in lymphocytes than what was described 
for IFN-treated epithelial cells. Whether the IFN-E2F/Rb axis contributes to persistent infection in 
lymphocytes has not been determined, but different and/or additional mechanisms of 
transcriptional repression likely regulate persistence in lymphocytes.  
Other mechanisms of viral transcriptional repression have been reported in AdV infection 
of epithelial cells that potentially link the metabolic state of the cell to regulation of persistent 
infection through NAD-dependent enzymes.  Sirtuins (NAD+-dependent Class III HDACs) have 
been implicated in regulation of AdV gene expression. Silencing RNA (siRNA) knockdown of all 
seven human sirtuins (SIRT1-7) has been shown to increase AdV-C5 titers by 1.5- to 3-fold (73). 
In the same vein, activation of sirtuins through resveratrol treatment inhibits adenovirus DNA 
replication(74,75). Another NAD+-dependent enzyme to have been studied in lytic infection is 
Poly(ADP-Ribose) Polymerase 1 (PARP1); the AdV E4orf4 protein has been found to increase 
production of viral progeny through inhibition of PARP1, which is activated by the infection-
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induced DNA damage response (DDR) (76). PARP-induced synthesis and attachment of long 
poly(ADP-ribose) chains to proteins has been shown to regulate cellular transcription through 
chromatin remodeling and modification of transcription factors (77,78). Whether sirtuins or 
PARP1 contribute to the transcriptional repression of persistent infection needs further 
investigation.  
2.6 Conclusion 
Given the unique interaction of AdV with lymphocytes, and the ubiquitous presence of 
AdV in the population, a more thorough understanding of the mechanisms that regulate its 
persistence and reactivation are needed. Overall, our data provide novel insight into metabolic 
factors that can influence adenoviral infections in activated human lymphocytes and reveal that 
modulation of the cellular NAD+/NADH ratio can de-repress adenovirus early and late gene 
expression in persistently-infected lymphocytes.  Blockade of CtBP binding with its PxDLS-
containing partners, including E1A, did not induce the same changes in AdV gene expression 
observed by direct manipulation of the NAD+/NADH ratios or lymphocyte activation. Thus, the 
increased E1A gene expression observed in T lymphocytes upon disruption of the CtBP interaction 
with PxDLS-binding partners likely represents one mechanism of a multi-factorial program of 
gene regulation occurring following metabolic shifts and lymphocyte activation.  
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3 CONTRIBUTIONS OF CLASS I, II, AND III HDACS TO VIRAL GENE 
REPRESSION DURING ADENOVIRUS PERSISTENT INFECTION 
3.1 Background 
Unlike the lytic adenovirus infection of epithelial cells, persistent infection of lymphocytes 
typically progresses to a non-lytic, “smoldering” infection in which replicating virus is rare (1-3). 
Lymphocytic cell line models of persistent infection have been established that exhibit long-term 
retention of high levels of viral genomes and very low protein expression (2,3). Interestingly, the 
persistent phase in these models has been shown to be regulated, in part, by transcriptional controls 
not seen in lytic infections. Several viral genes have been reported to display alternative patterns 
of expression when compared to lytic infections, suggesting specific programs of repression are 
present in persistent infections of lymphocytes (4-6).  
     Histone deacetylases (HDACs) play an important role in repression of cellular gene 
expression through the removal of acetyl groups from lysine residues on histone tails and 
condensation the chromatin structure (7).  The 18 HDACs expressed in human cells are divided 
into four classes based on their homology with yeast orthologs, and can be further categorized 
based on ion requirements at the catalytic site: Class I (HDAC 1, 2, 3, 8), Class II (HDAC 4, 5, 7, 
and 9), and Class IV (HDAC 11) are zinc (Zn2+)-dependent and Class III (Sirtuins 1-7) are 
nicotinamide adenine dinucleotide (NAD+)-dependent (7,8).  Class I HDACs are ubiquitously 
expressed nuclear proteins and typically have cell type-specific function as part of multi-subunit 
repressor complexes, such as Sin3, CoREST, Mi2/NuRD, and SMRT (9,10). Class II HDACs have 
cell type-specific expression, shuttle between the nucleus and cytoplasm and have limited catalytic 
activity compared to the Class I HDACs (9,11). Class II HDACs are further divided into subclass 
IIa and IIb, which contain one or two deacetylase domains, respectively (12).  Sirtuins are histone 
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deacetylases with a variety of other enzymatic activities in the cell including ADP ribosylation, 
desuccinylation, and demalonylation (13,14). The NAD+-dependence of sirtuins also links 
function to the metabolic state of the cell (13).   
      Similar to cellular chromatin, the chromatin structure for several DNA-virus genomes 
is also subject to regulation by HDACs, which has been shown to be important for latent or 
persistent infection and reactivation (reviewed in (15) and (9)). The CoREST complex containing 
HDAC1 has been shown to be important for the establishment of herpes simplex virus 1 (HSV) 
latency, and HSV protein ICP50 has been shown to displace HDAC1 from CoREST repressive 
complexes during reactivation (16). Human cytomegalovirus (CMV) latency has been shown to 
be regulated by hypoacetylation and HDAC3 at the major immediate early gene promoter (MIEP), 
and chromatin remodeling of this promoter leads to reactivation (9,17). Epstein Barr Virus (EBV) 
latency is strongly regulated by the myocyte enhancer binding factor 2 (MEF2) recruitment of 
HDAC4, 5, and 7 to the promoter of immediate early gene BZLF (18).  Kaposi’s sarcoma-
associated herpesvirus (KSHV) latency is regulated in part by HDAC1, 2, and 7 repression at the 
ORF50 promoter, the release of which induces reactivation (15). Although less is known about the 
chromatin structure of latent human papilloma virus (HPV), HDAC inhibitor trichostatin A (TSA) 
has been shown to upregulate expression from the HPV-16 long-control-region (LCR) (19). The 
sirtuins have also been shown to play a role in repression of DNA viruses both through broad anti-
viral mechanisms (13) and through specific manipulation of key viral genes.  Sirtuin-activator 
resveratrol (RV) has shown to inhibit early gene expression in HSV (20) and EBV (21), repress 
ORF50 in KSHV (22), and block replication of CMV (23). These mechanisms and additional 
known mechanisms involving Class I, II, and III HDACs in repression of viral and cellular gene 
expression in the life cycle of several DNA viruses are shown in Figure 3-1 (as reviewed in (24)).  
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Figure 3-1. Regulation of HDAC function during infection with DNA viruses.  
Based on mechanisms reviewed in (24) and (9). Figure modified from (24).  
 
Despite this body of work describing the activity of HDACs in regulating transcription 
during the life cycles of multiple viruses, little has been reported on the role of histone deacetylases 
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infection where regulation of activation of viral genes is more relevant. For long-term persistent 
infections or retention of AdV vectors, HDACs may have a larger impact on gene expression.   
    Most of what is known about Class I and II HDACs and their activity in regulation of 
AdV gene expression has been found through the use of HDAC inhibitors (HDACi).  Studies by 
other students in the Benson lab have revealed that Class I and II HDACs play a role in repression 
of AdV gene expression in persistently-infected cells; TSA upregulates transcription of several 
viral genes (Wilms et al., submitted).  Published studies from other labs have evaluated the effects 
of Class I and II HDAC inhibitors (HDACi) on expression from AdV vector-delivered transgenes.  
While HDACi have been reported to increase the efficiency of adenovirus-based oncolytic viral 
therapy through the increased expression of viral receptors on the cell surface (25), HDACi also 
have been reported to increase expression of genes delivered in the AdV vector (26,27). Various 
Class I and II HDACi have been used successfully to upregulate transgene expression in numerous 
cell types and lines from a range of host species, including primary bovine or rat muscle cells (28),  
human thyroid carcinoma cell lines (27), mouse neuroblastoma cells, HeLa cells, human 
neuroblastoma cells, primary human dendritic cells, keratinocytes, and primary rat astrocytes (29), 
and rat neurons (30). The broad diversity of vector constructs, and wide array of cellular 
backgrounds, in which Class I and II HDACi increase gene expression suggest Class I and II 
HDACs act in a non-specific manner to silence foreign DNA.  
     Sirtuins have also been implicated in regulation of AdV gene expression. Silencing 
RNA (siRNA) knockdown of all seven sirtuins has been shown to increase AdV-C5 titers by 1.5- 
to 3-fold (13). In the same vein, activation of sirtuins through RV treatment inhibits adenovirus 
DNA replication of wild-type and vector viruses (30-32). How the sirtuins function to repress AdV 
replication has not been studied. 
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     Based on these previous reports, we hypothesized that HDACs would be involved in 
repression of AdV gene expression in persistently-infected lymphocyte cell lines. In this chapter, 
we first show the differences in expression of Class I and II HDACs between epithelial and 
lymphocytic cell lines. We additionally show that Class I HDACs are involved in repression of 
late AdV genes but have found no evidence of Class II HDAC enzymatic activity involvement in 
AdV repression. Surprisingly, sirtuins seem to positively regulate E1A, but are conversely involved 
in repression of late genes. This is the first study to report the contributions of these enzymes 
towards maintenance of the persistent AdV-infection of lymphocytes.  
 
3.2 Materials and Methods 
Cell Lines and Culture 
The human lung carcinoma cell line A549 was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). BJAB (EBV-negative Burkitt’s lymphoma, (33)) and Jurkat 
(T cell Acute Lymphoblastic Leukemia [ALL]) were also obtained from the ATCC. KE37 
(immature T cell ALL) cells were purchased from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Braunschweig, Germany). A549 cells were grown in Dulbecco’s modified 
Eagle medium (DMEM) with 4.5μg of glucose per ml, 10% fetal calf serum (FCS), and 10 mM 
glutamine under 8% CO2. BJAB, Jurkat, and KE37 cells were grown in RPMI medium 
supplemented with 10% FCS and 10 mM glutamine under 5% CO2. Cells were routinely evaluated 
to ensure the absence of mycoplasma and lymphocyte cell lines were authenticated by Genetica 
Cell Line Testing (Burlington, NC). 
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Adenoviruses 
The AdV-C5 mutant virus strain AdV-C5-dl309 is phenotypically wild-type in cell culture 
and was obtained from Tom Shenk (Princeton University, Princeton, NJ. AdV-C5-dl309). AdV-
C5-dl309 lacks genes necessary for evading adaptive immune attack (E3 RIDα and RIDβ proteins 
as well as the 14,700-molecular-weight protein [14.7K protein]) in infected hosts (34).  
 
Infection of lymphocytes with adenovirus 
Infection of lymphocyte cell lines with adenovirus was performed as described previously 
(35) with minor modifications. Lymphocytes were collected and washed in serum-free (SF) RPMI 
medium, and cell density was adjusted to 107 cells per mL in SF-RPMI medium. Virus was added 
to the cell suspension at 50 PFU/cell, spun for 45 minutes at 1000 x g at 25°C, and resuspended 
by agitation. Cells were then incubated at 37°C for 1.5 hours with gently flicking every 30 minutes. 
The infected cells were washed three times with complete RPMI medium and then resuspended in 
complete RPMI medium at 5x105 cells per mL for culture. Cell concentration and viability were 
monitored throughout the infection. Replicates for experiments were obtained from independent 
infections. 
 
Optimizing treatment doses (See Appendices) 
Drug treatment concentration and time of exposure were optimized for all cell lines. For 
lymphocytic cell lines, cells were seeded at a density of 3 x 105 and 1 x 105 cells per mL, 
respectively, in complete medium supplemented with treatment doses of drugs. Treatment drugs 
and doses tested include Trichostatin A (TSA, Pan HDAC inhibitor, Sigma-Aldrich, [50, 175, 
300nM]), Tacedinaline (Class Ia inhibitor, Selleck Chemicals, [2.5, 5, 7, 10𝜇M]), TMP195 (Class 
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IIa inhibitor, Cellagen Technologies, [300, 500, 1000, 1500nM]), Tubacin (Class IIb HDAC6 
inhibitor, Santa Cruz Biotechnology, [1, 2, 4𝜇M]), Resveratrol (Sirtuin activator, Calbiochem, [5, 
10, 20, 40uM]), and Sirtinol (SIRT1 and SIRT2 inhibitor, Selleck Chemicals, [25, 50, 75𝜇M]). 
Cell growth and viability were assessed by Trypan blue exclusion at 24 and 48 hours (see 
Appendices). Experiments utilized the following doses which maintained the viability indicated at 
48 hours: TSA-175nM, >50%; Tacedinaline-5uM, >70%; TMP195-1000nM, >90%; Tubacin-
2uM, >60%, Resveratrol-20uM, >40%.  Sirtinol was particularly toxic to T cell lines and a 
minimum dose of 25uM was used to keep >15% viability and to see transcriptional effects.  
 
RT-qPCR 
RT-qPCR was performed as described previously with minor modifications (36). Briefly, 
total RNA was isolated from 1 x 106 cells using the RNeasy Mini Kit (Qiagen Inc., Valencia, CA) 
with RNase-free DNase treatment (Qiagen). After spectrophotometric quantification, 200ng of 
RNA was reverse transcribed into cDNA in 20𝜇L reactions (Maxima First Strand cDNA Synthesis 
Kit, Thermo Fisher Scientific, Waltham, MA).  RT-enzyme negative controls were included for 
each reaction. Primers and probes were obtained from Integrated DNA Technologies (Coralville, 
IA), with sequences specified below. Each cDNA sample was run in duplicate qPCR reactions 
using the Maxima Probe/ROX qPCR Master Mix (Thermo Fisher Scientific) with cycling 
conditions as described.  For all experiments expression of our housekeeping gene (eukaryotic 
translation initiation factor 1, EIF1) was unchanged by treatment and changes to viral gene 
transcription were assessed as relative amounts of target (fold-change over untreated) as 
2$(∆'(,*+,-*,.$∆'(,/0*+,-*,.) = 2$∆∆'( as described in (37).  
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Primers and Probes: 
E1A (Sense sequence, 5’- GTTAGATTATGTGGAGCASCCC-3’, anti-sense sequence, 
5’-CAGGCTCAGGTTCAGACAC -3’, probe sequence, 5’-6 FAM-
ATGAGGACCTGTGGCATGTTTGTCT-3IABkFQ-3’) 
 
E3GP19K (Sense sequence, 5’-TTTACTCACCCTTGCGTCAG-3’, anti-sense sequence, 
5’-GCAGCTTTTCATGTTCTGTGG-3’, probe sequence, 5’-6 FAM-
CTGGCTCCTTAAAATCCACCTTTTGGG-3IABkFQ-3’) 
 
TLP HEXON (Sense sequence, 5’-AAAGGCGTCTAACCAGTCAC-3’, anti-sense 
sequence, 5’-CCCGAGATGTGCATGTAAGAC-3’, probe sequence, 5’-6 FAM-
CGCTTTCCAAGATGGCTACCCCT-3IABkFQ-3’) 
 
EIF1 (Sense sequence, 5’- GATATAATCCTCAGTGCCAGCA-3’, anti-sense sequence, 
5’-GTATCGTATGTCCGCTATCCAG-3’, probe sequence, 5’-6 FAM-
CTCCACTCTTTCGACCCCTTTGCT-3IABkFQ-3’) 
 
Quantitative real time PCR analysis of viral DNA levels 
     Infected or uninfected control cells were washed in phosphate-buffered saline (PBS) 
and 5 x 105  cells for each sample were lysed in 100μL of NP-40–Tween buffer containing 
proteinase K, as described in (38). Samples were tested by real-time PCR for a region of hexon 
gene that is conserved among species C adenovirus serotypes. Samples were run in duplicate for 
each independent experiment, with cycling conditions as described. Viral genome numbers were 
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quantified by comparison to an Ad2 DNA standard curve and normalized relative to GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) expression to account for small differences in cell 
input (38).   
 
Flow cytometry 
 Cells were fixed with 1% paraformaldehyde, and membranes permeabilized with 0.2% 
Tween in PBS. Intracellular staining for AdV hexon protein was done with primary anti-hexon 
antibody (MAB 8051, EMD Millipore Corp, Billerica, MA), and secondary allophycocyanin 
(APC)-conjugated anti-mouse IgG antibody (A865, Invitrogen-Life Technologies, Eugene, OR). 
A mouse isotype IgG1, 𝜅 antibody (557273, BD Pharmingen) was used to control for non-specific 
antibody binding.  Detection of antibody-conjugated APC was performed on LSR Fortessa flow 
cytometer (Becton Dickinson) and analyzed using FlowJo software (Becton Dickinson).   
 
Immunoblots for protein detection 
     Protein lysates were prepared using RIPA buffer (Sigma-Aldrich) with 
protease/phosphatase inhibitors (Cell Signaling Technologies), and protein concentrations were 
quantified using a BCA protein assay (Thermo Scientific).  Thirty ug of protein was separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5 to 12% 
polyacrylamide gels (Mini-PROTEAN TGX gels, BioRad, Hercules, CA). Proteins were 
transferred onto nitrocellulose membranes (Thermo Scientific) overnight at 30mV at 4°C. 
Following confirmation of protein transfer with Ponceau S staining (Aqua Solutions, Deer Park, 
TX), membranes were blocked at room temperature (RT) with 5% bovine serum albumin (BSA) 
for 1 hour, washed three times with Tris-Buffered-Saline with 1% Tween (TBST), and incubated 
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with primary antibodies on a rocker overnight on at 4°C. Following three washes with TBST, 
membranes were incubated with secondary HRP-conjugated antibodies for 1 hour at RT. 
Membranes were washed three times with TBST, the HyGLO HRP chemiluminescent reagent 
(Denville, Quebec, CA) used as substrate, and signal detected using x-ray film (MTC Bio). 
Primary antibodies (rabbit) were all obtained from Cell Signaling (Danvers, MA): 
HDAC1(D5C6U), HDAC2 (D6S5P), HDAC3 (D2O1K), HDAC4 (D8T3Q), HDAC5 (D1J7V), 
HDAC6 (D21B10), HDAC7 (D4E1L), and b-actin (D6A8). Secondary antibody used was also 
from Cell Signaling: HRP-linked anti-rabbit IgG (7074). 
 
3.3 Results 
3.3.1 Class I HDACs are ubiquitously expressed, but Class II HDACs are  
differentially expressed across cell-line models of infection 
Cell-line models of AdV infection have different infection phenotypes. Infection of A549 
epithelial cells progresses rapidly towards lysis. Infection of the Jurkat T cell line also produces a 
lytic infection, but much more slowly than with A549 (3). BJAB (B cell) and KE37 (T cell) lines 
establish a persistent infection marked by high viral genome copy number and low amounts of 
detectable viral protein, and therefore would be considered the most highly repressed (3).  
   Using western blot, we assessed the amounts of Class I HDACs (1, 2, 3) and Class II 
HDACs (4, 5, 6, and 7) present in the different cell lines prior to infection to see if there was any 
correlation between HDAC expression levels and infection phenotype across the A549, Jurkat, 
KE37, and BJAB cell lines (Figure 3-2). In addition, we tested HDAC protein levels in 
persistently-infected KE37 and BJAB to see if infection altered expression.   
 
85 
 
Figure 3-2. Class I and II HDAC protein levels in cell line models of AdV infection. 
Two persistently-infected cell lines (iKE37 and iBJAB, >50 days post-infection (dpi)) are 
also shown. 𝛽-actin is shown as a loading control.  
 
 
Class I HDACs were uniformly expressed across all cell lines tested, with the exception of 
an additional HDAC2 isoform present in A549 cells. However, differences in the Class II HDACs 
were detected, the most notably for HDAC 4 and 7. BJAB appeared to have reduced levels of 
HDAC4 compared to the epithelial and T cell lines. Interestingly, the amount of HDAC7 present 
had a strong inverse correlation with the infection outcome; A549 had the lowest expression and 
has the quickest progression to lysis, whereas the BJAB cell line had the highest expression of 
HDAC7 and typically shows the highest degree of viral repression (see Chapter 2, Figure 2-1B). 
Only trace amounts of HDAC5 could be detected in all of these cell lines (Figure 3-2), which 
seemingly contradicts what has been reported for these cell types; although HDAC5 is most highly 
expressed in heart, skeletal muscle, and brain (12),  B and T cells have been shown to express 
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detectable levels (39). Importantly, persistent infection did not substantially alter expression of the 
HDACs we tested.  
3.3.2 Enzymatic activity of Class I HDACs, but not Class II, is involved in repression 
of AdV genes in persistently-infected lymphocyte cell lines.  
We have previously reported that pan-HDAC inhibitor TSA, which has been reported to 
inhibit both Class I and Class II HDACs, upregulates AdV gene expression in persistently-infected 
cells (Wilms et al., submitted). Here we tried to identify the specific class of HDACs responsible 
for the repression of viral genes.  We treated persistently-infected cells, greater than 50 days post-
infection, with different HDAC inhibitors (Tacedinaline - Class I HDAC inhibitor, TMP195 - 
Class IIa HDAC inhibitor, or TSA – pan-HDAC inhibitor;  specificity shown in Figure 3-3) for 48 
hours and assessed changes to viral immediate early gene E1A, early gene E3, or late gene hexon 
using RT-qPCR. 
 
Figure 3-3. Inhibitors of Class I and II HDACs. 
Red square indicates a potency (half-maximum inhibitory concentration, IC50) of < 2uM.  
Modified from (Lobrera 2013). 
 
 
These treatment drugs function by inhibiting the deacetylase activity of the HDACs (40).  
The Class I inhibitor induced a robust upregulation of E3 (2- to 4-fold) and hexon (3- to 4-fold), 
on the same scale or higher than the TSA treatment in persistently-infected BJAB (Figure 3-4). 
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E1A did not respond to the Class I inhibitor in the BJAB cell line, but small increases in E1A 
expression could be detected in the persistently-infected KE37 cell line.  Treatment with the Class 
IIa inhibitor did not appear to alter viral gene expression in either cell line, indicating that 
enzymatic activity of the Class IIa HDACs is not contributing to viral gene repression (Figure       
3-4). 
 
 
Figure 3-4. Treatment with Class I, but not Class IIa, HDAC inhibitors increases viral 
gene expression in persistently-infected cell lines. 
Infected BJAB (55dpi) and KE37 (81dpi) were treated with 5𝜇M tacedinaline (Class I), 
1𝜇M TMP195 (Class IIa), or 175nM TSA (pan) for 48 hours. Expression of viral genes E1A, E3, 
and hexon were compared to housekeeping gene EIF1 and assessed by RT-qPCR as described in 
Materials and Methods. Untreated values for each gene were set to 1. Dotted line demarks a value 
of 1 signifying no relative change in expression level. One representative experiment of 2 
biological repeats is shown for each cell line. Error bars denote standard deviation on duplicate 
wells.    
 
 
 
Because the increases in viral gene expression with TSA treatment could be the result of 
inhibition of Class IIb HDACs as well (40), we next investigated whether inhibition of Class IIb 
HDACs alone would induce changes to viral gene expression. There currently is no HDAC10 
inhibitor available, but there are several highly selective inhibitors of HDAC6, including tubacin 
and tubastatin A (41).  We treated persistently-infected cells with tubacin or TSA for 48 hours and 
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assessed viral gene expression using RT-qPCR.  Like Class IIa HDACs, the Class IIb inhibitor 
again had very little effect on expression of viral genes in either cell line (Figure 3-5). Therefore, 
although we did not investigate the contribution of Class IIb HDAC10 or Class IV HDAC11 
towards viral gene repression, we concluded that deacetylase activity of Class I HDACs, and not 
Class II, is largely responsible for the viral gene repression that is alleviated with TSA treatment. 
 
 
Figure 3-5. Treatment with HDAC6 inhibitor (Class IIb) does not alter viral gene 
expression. 
Infected BJAB (64dpi) and KE37 (78dpi) were treated with 2𝜇M tubacin (Class IIb, 
HDAC6), or 175nM TSA (pan) for 48 hours. Expression of viral genes E1A, E3, and hexon were 
compared to housekeeping gene EIF1 and assessed by RT-qPCR as described in Materials and 
Methods. Untreated values for each gene were set to 1. Dotted line demarks a value of 1 signifying 
no relative change in expression level. One representative experiment of 2 biological repeats 
shown for each cell line. Error bars denote standard deviation on replicate wells.    
 
 
3.3.3 Activating Class III HDACs (sirtuins) with resveratrol upregulates E1A 
expression. 
We described in Chapter 2 (Figure 2-4) that treatment with nicotinamide (NAM) shifts the 
NAD+/NADH ratio in persistently-infected cells, and that nicotinamide induces upregulation of 
viral genes E3 and hexon in persistently-infected BJAB cells, and of E1A, E3, and hexon in 
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persistently-infected KE37 cells. Nicotinamide treatment also acts as an inhibitor of the sirtuin 
family of HDACs, which could contribute to the release of repression of AdV gene expression 
(42).  As sirtuins have been reported to have broad-antiviral activity including the repression of 
adenovirus (13), we further investigated the role sirtuins play in persistent infection. Persistently-
infected cells were treated with sirtuin-activator resveratrol (RV) and changes in viral gene 
expression were determined using RT-qPCR (Figure 3-6). Surprisingly, RV-induced sirtuin 
activation had opposing effects on E1A and hexon expression.  RV treatment caused an 
approximately 2-fold down-regulation of viral late gene hexon in both cell lines, a result that likely 
comprises the anti-AdV effect of sirtuins (13,31).  Surprisingly, E1A was upregulated by RV 
treatment by 1.7-fold in iBJAB and 2.8-fold in iKE37 and to similar levels in replicate experiments 
(data not shown). The E3 gene was largely unresponsive to RV treatment indicating that sirtuins 
are not involved in regulation of this promoter. Together, these data suggest that the sirtuins play 
a role in the repressive transcriptional regulation of AdV gene expression during persistent-
infection, but act primarily through repression of late, rather than early genes. Similar to results in 
Chapter 2, these data point to differential regulation across early and late viral genes.  
3.3.4 Inhibiting SIRT1 and SIRT2 with sirtinol upregulates E3 and hexon in 
persistently-infected cell lines.  
Sirtuins (SIRT1-7) localize to different subcompartments within the cell.  SIRT1 is 
primarily nuclear, but shuttles between the nucleus and the cytoplasm (43). SIRT2 is primarily 
cytoplasmic, but moves to the nucleus during certain phases of the cell cycle (44). SIRT3, SIRT4, 
and SIRT5 are located in the mitochondria, although a small fraction of SIRT3 resides in the 
nucleus (44). SIRT6 localizes to the nucleus, and SIRT7 to the nucleolus (43). SIRT1, SIRT2, 
SIRT6 have the most well-studied roles in chromatin remodeling (44,45).  In order to further 
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identify which sirtuins were involved in repression of the AdV gene expression, we treated 
persistently-infected cells with sirtinol, which inhibits SIRT1 and SIRT2 (42), and assessed viral 
gene expression through RT-qPCR (Figure 3-7).  
 
Figure 3-6. Activating sirtuins with resveratrol upregulates E1A and down-regulates 
hexon in persistently-infected lymphocytic cell lines. 
Cells were treated with 20𝜇M RV for 48 hours (iBJAB) or 24 hours (iKE37), and changes 
in viral gene expression evaluated using RT-qPCR as described in Materials and Methods.  One 
of 4 replicates is shown for iBJAB (> 99 dpi), and one of two replicates is shown for iKE37 (> 80 
dpi). All gene expression shown relative to the untreated sample, which was set to one. Dotted line 
demarks a value of 1 signifying no relative change in expression level. Error bars show standard 
deviation on replicate wells.  
 
 
 
 
Figure 3-7. Inhibition of SIRT1 and SIRT2 with sirtinol upregulates viral gene 
expression. 
Cells were treated with 25𝜇M sirtinol for 48 hours, and changes in viral gene expression 
evaluated using RT-qPCR as described in Materials and Methods. Persistently-infected BJAB 
were at 60dpi, and KE37 were at 77dpi.  One experiment for each cell line was performed. All 
gene expression shown relative to the untreated sample, which was set to one. Dotted line demarks 
a value of 1 signifying no relative change in expression level.  
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Inhibiting SIRT1 and SIRT2 with sirtinol upregulated E3 and hexon approximately 1.5-
fold in iBJAB cells, but E1A was not altered by treatment (Figure 3-7).  Sirtinol also upregulated 
E3 and hexon in iKE37 cells, but to a higher degree (2.5-fold). Interestingly, E1A was also 
upregulated approximately 2.5-fold by sirtinol treatment in iKE37 cells (Figure 3-7).  Although 
requiring confirmation with replicate experiments, these results show SIRT1 and SIRT2 contribute 
to repression of E3 and hexon in persistenty-infected cells. SIRT1 and SIRT2 also contribute to 
repression of E1A in KE37 cells.  
    Interestingly, E3 was upregulated in both cell lines when SIRT1 and SIRT2 were 
inhibited with sirtinol (Figure 3-7), but E3 was unaffected with RV-induced sirtuin activation 
(Figure 3-6).  This difference in effect may have to do with different modes of action and 
specificity of the two compounds.  Sirtinol is highly specific for SIRT1 and SIRT2, and works by 
blocking catalytic activity (46). Resveratrol, on the other hand, activates predominantly SIRT1 and 
functions allosterically by inducing a conformational change in the sirtuin and favoring cleavage 
of the substrate (47). Because SIRT1 activity is involved in a number of signaling pathways 
including NF-𝜅B and forkhead O family (FOXO) (48), direct inhibition of SIRT1 by sirtinol likely 
has off-target effects that induce an additive upregulation of viral gene expression. Further 
investigation of direct SIRT1 effects through histone modifications or ChIP detection of SIRT1 at 
the E3 promoter will be important to confirm SIRT1 involvement in the regulation of this viral 
gene. 
3.3.5 Long-term sirtuin inhibition with nicotinamide does not prevent establishment of 
persistent infection.  
AdV infection of lymphocytic cell lines begins with an acute infection in which high levels 
of viral proteins are expressed, followed by silencing of viral gene expression as the cells enter the 
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persistent phase of infection (3).  Because sirtuins were found to be involved in repression of AdV 
genes (Figure 3-7), we next investigated whether continued inhibition of sirtuin activity with long-
term NAM treatment would prevent the silencing of viral gene expression and block transition to 
persistent infection.  First, we determined that our lymphocytic cell lines could be treated with 
NAM for up to 40 days with no impact on viability (data not shown). To determine the effects of 
sirtuin inhibition of viral gene expression, NAM was added to cell culture medium 24 hours prior 
to infection, and treated cells were kept in the NAM-supplemented medium for the full 37 days of 
the experiment. As Figure 3-8A shows, NAM treatment had little effect on hexon expression 
during the acute phase (Days 1-10) of infection when compared to untreated infected cells. By Day 
20 in the untreated samples, the number of cells expressing hexon was reduced to less than one-
third the peak frequency, from 90% to 25% in the KE37 cells and from 50% to 10% in the BJAB 
cells (Figure 3-8A), showing the infections were entering persistent phase as previously reported 
(3). Interestingly, NAM treatment dramatically increased the number of KE37 cells expressing 
hexon at Day 20, approximately 60% compared to 25% in untreated cells. A small increase in 
number of BJAB cells expressing hexon was also seen with NAM treatment at Day 20 post-
infection, 17% of NAM treated compared to 11% of untreated cells.  This small increase in 
frequency of hexon-expressing BJAB cells at Day 20 was seen in an independent biological 
replicate (data not shown) and is therefore not likely to be an artifact of the experimental set up. 
To confirm that long-term NAM treatment did not alter viral DNA levels, relative quantities of 
viral genomes in each sample were assessed by qPCR and found to be unchanged by treatment 
(Figure 3-8B). These data show that sirtuins play a role but are not the dominant transcriptionally 
repressive force in the silencing of viral gene expression and establishment of persistent infection. 
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A 
 
B 
 
Figure 3-8. Long-term sirtuin inhibition with NAM does not prevent establishment of 
persistent infection. 
A) Percent of cells expressing hexon.  Cells were untreated or switched to growth medium 
supplemented with 3mM NAM 24 hours prior to infection. Cells were infected with AdV-C5-
dl309 at MOI 50 by standard spin infection as described in Materials and Methods.  Percent of 
hexon-positive cells was determined using flow cytometry. B) Relative quantities of viral genomes 
at Day 37. Viral DNA was assessed by qPCR as described in Materials and Methods, and 
normalized to cellular housekeeping gene GAPDH.  Error bars show standard deviation on 
replicate wells. One representative experiment of two biological repeats with similar results 
shown.  
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3.4 Discussion 
We have shown in this chapter that Class I HDACs (Figure 3-4) and sirtuins (Figures 3-6 
to 3-8) contribute to the transcriptional repression of AdV gene expression during persistent 
infection of lymphocytic cell lines. These findings join the body of work showing that Class I 
HDACs and sirtuins regulate transcription during viral latency or persistent infection by a number 
of other DNA viruses, including EBV, CMV, KSHV, and HPV (reviewed in (15) and (9)). Our 
experimental approach made use of an array of commercially available HDAC inhibitors and 
activators to provide the first evidence of the contribution of these repressive enzymes to the 
regulation of AdV persistent infection. We have additionally shown that HDAC activity is more 
prevalent in repressing the major late promoter than the early genes, and that the degree of HDAC 
involvement may be cell-type specific (Figure 3-7).   
      The current understanding of the functions of Class II HDACs, especially Class IIa, is 
that the predominant role these proteins play in regulation of cellular gene expression is 
noncatalytic, but that they promote histone deacetylation through interaction with Class I HDAC3 
and the SMRT/NCoR repressive complexes (11,40). However, the Class II HDACs do retain a 
functional catalytic site, but the biological function of this activity has not been conclusively 
determined.  Interestingly, the catalytic activity of Class IIa HDAC5 was recently found to be 
involved in stress-induced regulation of gene expression in cardiomyocytes, not through histone 
deacetylation, but through regulation of ROS signaling (49).  Through treatment of persistently-
infected cells with the Class IIa HDAC inhibitor TMP195 we showed that the catalytic activity of 
these enzymes does not influence the expression of AdV genes during a persistent infection (Figure 
3-4).  
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     While the Class I HDACs were uniformly expressed across the cell line models of 
infection, there were differences in expression of the Class II HDACs (Figure 3-2).  Notably, the 
protein levels of HDAC7 appear to correlate with the degree of viral gene repression, with the 
BJAB cell line having the highest level of HDAC7 expression (Figure 3-2) and the highest degree 
of repression (Chapter 2, Figure 2-1B).  HDAC7 is most highly expressed in lymphocytes and is 
important for regulation of B and T cell development (50,51) and for cytokine expression in T 
cells (52). In addition, immune cell activation with PMA/iono treatment, which we have shown 
upregulates viral gene expression (Chapter 2, Figure 2-2B), causes a rapid relocalization of 
HDAC7 from the nucleus to the cytoplasm (39), potentially releasing repressive complexes from 
the AdV genome.  We have not determined whether the Class II HDACs affect AdV gene 
expression through the formation and recruitment of repressive complexes, but this question and 
the involvement of HDAC7 will be an exciting area of research to pursue.  
     RV activation of SIRT1 was found to downregulate late gene hexon approximately two-
fold (Figure 3-6).  RV treatment has previously been shown to inhibit production of infectious 
particles in HEK293 cells, but the mechanism of action was not investigated (31).  Our data suggest 
that downregulation of expression from the major late promoter, which drives the expression of 
the structural proteins, may account for the RV-induced reduction in viral titer. Investigation of 
the effect of RV treatment on the expression of the other late proteins is needed to confirm this 
finding.  
   The fact that RV treatment and the resulting SIRT1 activation in persistently-infected 
cells upregulates E1A expression is surprising (Figure 3-6), and suggests that the virus may have 
adapted the sirtuin anti-viral activity to its advantage.  E1A expression and downstream early gene 
activation were recently found to be repressed by lysine acetyltransferase Tip60, through H4 
96 
acetylation and retention of viral protein VII at the E1A promoter (53). SIRT1 has been found to 
be a regulator of Tip60; SIRT1-orchestrated deacetylation of Tip60 reduces its HAT activity and 
can lead to proteosomal degradation (44,54). In addition, SIRT1 deacetylates H4 at K16 (43,44).  
Based on these studies, it is possible that SIRT1 activation could result in reduced activity of Tip60 
and deacetylation of H4 at the E1A promoter, increasing expression of E1A. Whether a 
Tip60/H4Ac/VII axis contributes to repression of E1A in persistently-infected cells, and whether 
the cellular anti-viral activity of SIRT1 may actually facilitate E1A expression are interesting 
questions to answer with future work. 
 
3.5 Conclusion 
We have shown in this chapter that Class I and III HDACs contribute to the transcriptional 
repression of the AdV genome characteristic of persistent infection of lymphocytes.  We have 
additionally shown that while sirtuins repress late gene expression, sirtuins may have a paradoxical 
activity at the E1A promoter, leading to enhanced expression of the critical E1A proteins. Long-
term inhibition of sirtuin function did not prevent the establishment of persistent infection of 
lymphocytes, indicating that persistence is likely regulated by complex and multifactorial 
mechanisms. 
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4 LIMITATIONS OF CURRENT APPROACHES FOR THE STUDY OF 
ADENOVIRUS PERSISTENT INFECTION 
4.1 Background 
Persistent adenovirus (AdV) infection of mucosal lymphocytes is marked by retention of 
viral double-stranded DNA genomes with little to no production of viral proteins or infectious 
particles (1,2). While close to 80% of pediatric patients undergoing tonsillectomy test positive for 
AdV DNA in extracted lymphocytes, the frequency of infected cells in those samples is quite low, 
ranging from 3 to 3,400 cells per 107 lymphocytes (2). Among infected cells from a single patient 
sample, large variation in genome copy number per cell has been seen, with an occasional infected 
cell containing up to 10-fold more viral DNA than the other infected cells (2). Because a 
correlation was found between genome copy number and the presence of replicating virus in these 
samples, it is likely that even among these rare infected cells, the viral genome exists in different 
active states, making study of the molecular details of the persistent infection in primary 
lymphocytes challenging (2).    
     Lymphocytic cell line models of persistent infection similarly harbor viral genomes 
with low or undetectable protein expression for months to years in culture and offer a more readily-
accessible resource to study the mechanics of persistent infection (3,4). Cell-line use allows many 
aspects of cell culture and infection to be controlled, and continuous cell division generates ample 
material for experimentation purposes with the option for long-term study. Even with the relative 
ease-of-use of cell-line models, challenges remain for answering some specific questions that arise 
in studying persistent AdV infection of lymphocytes.   
     First, to reduce variability in any number of outcome measures from experiment-to-
experiment, using replicates with similar frequencies of infected cells is desirable. For our 
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purposes, we were interested in routinely assessing the frequency of infected cells and correlating 
this with the level of viral gene expression to make distinctions between smoldering persistent 
infections versus true latently-infected cells.  However, determining the number of infected cells 
is not trivial; current techniques are labor intensive and expensive, which limits routine 
implementation in the lab. This chapter will discuss these current techniques, and our attempts to 
use a GFP-expressing virus to determine the frequency of infected cells in culture.  Secondly, we 
wanted to determine the amount of viral gene expression on viral protein level which was difficult 
to ascertain using current antibody-based techniques. Few commercially-produced antibodies 
targeting AdV non-structural proteins are available, and this chapter will document challenges 
with non-specific binding of currently available antibodies, which impeded our ability to address 
this question. 
 
4.2 Materials and Methods 
Cell Lines and Culture 
The human lung carcinoma cell line A549 was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA). BJAB (EBV-negative Burkitt’s lymphoma, (5)) and Jurkat (T 
cell Acute Lymphoblastic Leukemia [ALL]) were also obtained from the ATCC. KE37 (immature 
T cell ALL) cells were purchased from the German Collection of Microorganisms and Cell 
Cultures (DSMZ, Braunschweig, Germany). A549 cells were grown in Dulbecco’s modified Eagle 
medium (DMEM) with 4.5μg of glucose per ml, 10% fetal calf serum (FCS), and 10 mM 
glutamine. BJAB, Jurkat, and KE37 cells were grown in RPMI medium supplemented with 10% 
FCS and 10 mM glutamine. Cells were routinely evaluated to ensure the absence of mycoplasma 
and lymphocyte cell lines were authenticated by Genetica Cell Line Testing (Burlington, NC). 
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Adenoviruses 
The AdV-C5 mutant virus strain AdV-C5-dl309 is phenotypically wild-type in cell culture 
and was obtained from Tom Shenk (Princeton University, Princeton, NJ. AdV-C5-dl309). AdV-
C5-dl309 lacks genes necessary for evading adaptive immune attack (E3 RIDα and RIDβ proteins 
as well as the 14,700-molecular-weight protein (14.7K protein)) in infected hosts (6). Ad5GFP, 
kindly donated by André Lieber (University of Washington), is a mutant virus containing a 
cytomegalovirus promoter-driven enhanced green fluorescent protein (GFP) gene inserted into the 
E3 region (7).  This virus was constructed in the pJM17 background (personal communication 
from Dr. Lieber, August 13, 2019), and the E3 genes of pJM17 are largely intact, but nonfunctional 
(8). 
 
Infection of Lymphocytes with Adenovirus 
Infection of lymphocyte cell lines with adenovirus was performed as described previously 
(9) with minor modifications. Lymphocytes were collected and washed in serum-free (SF) RPMI 
medium, and cell density was adjusted to 107 cells per mL in SF-RPMI medium. Virus was added 
to the cell suspension at 50 PFU/cell, spun for 45 minutes at 1000 x g at 25°C, and resuspended 
by agitation. Cells were then incubated at 37°C for 1.5 hours with gently flicking every 30 minutes. 
The infected cells were washed three times with complete RPMI medium and then resuspended in 
complete RPMI medium at 5x105 cells per mL for culture. Cell concentration and viability were 
monitored throughout the infection. Replicates for experiments were obtained from independent 
infections. 
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Flow Cytometry 
Cells were fixed with 1% paraformaldehyde, and membranes permeabilized with 0.2% 
Tween in PBS. Intracellular staining for AdV hexon protein was done with primary anti-hexon 
antibody (MAB 8051, EMD Millipore Corp, Billerica, MA), and secondary allophycocyanin 
(APC)-conjugated anti-mouse IgG antibody (A865, Invitrogen-Life Technologies, Eugene, OR). 
A mouse isotype IgG1, 𝜅 antibody (557273, BD Pharmingen) was used to control for non-specific 
antibody binding.  Detection of antibody-conjugated APC and expressed GFP was performed on 
a LSR Fortessa flow cytometer (Becton Dickinson) and analyzed using FlowJo software (Becton 
Dickinson).   
 
Fluorescent Imaging Technology 
In fresh cell samples, GFP expression and frequency of GFP-positive cells were assessed 
using the Cellometer Auto2000 (Nexcelom Bioscience). Uninfected cells were used as a negative 
control. 
       
Immunoblots for protein detection 
Protein lysates were prepared using RIPA buffer (Sigma-Aldrich) with 
protease/phosphatase inhibitors (Cell Signaling Technologies), and protein concentrations were 
quantified using a BCA protein assay (Thermo Scientific).  Thirty ug of protein was separated by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 7.5 to 12% 
polyacrylamide gels (Mini-PROTEAN TGX gels, BioRad, Hercules, CA). Proteins were 
transferred onto nitrocellulose membranes (Thermo Scientific) overnight at 30mV at 4°C. 
Following confirmation of protein transfer with Ponceau S staining (Aqua Solutions, Deer Park, 
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TX), membranes were blocked at room temperature (RT) with 5% bovine serum albumin (BSA) 
for 1 hour, washed three times with Tris-Buffered-Saline with 1% Tween (TBST), and incubated 
with primary antibodies on a rocker overnight at 4°C. Following three washes with TBST, 
membranes were incubated with secondary HRP-conjugated antibodies for 1 hour at RT. 
Membranes were washed three times with TBST, the HyGLO HRP chemiluminescent reagent 
(Denville, Quebec, CA) used as substrate, and signal detected using x-ray film (MTC Bio). Anti-
E1A antibody (Ad2/Ad5, clone M73) was generously provided by David Ornelles (Wake Forest 
University). Anti-E2 DNA-binding protein antibody (clone B6-8) was kindly provided by Arnold 
Levine (Princeton University) (10). Anti-b-actin monoclonal antibody (clone D6A8) was from 
Cell Signaling (Danvers, MA). Secondary antibodies used were also from Cell Signaling: HRP-
linked anti-rabbit IgG (7074) and HRP-linked anti-mouse IgG (7076S). 
 
4.3 Results:  Part A - Determining the Frequency of AdV-Infected Cells in a Persistently-
Infected Cell Culture 
No AdV gene product, either mRNA, non-coding (nc)RNA, or protein, has been found to 
be associated with persistent infection, so current methods to determine the infection status of a 
cell require detection of viral DNA.  The most sensitive technique is the limiting-dilution assay; 
infected cells are “diluted” at different ratios with non-infected cells, lysed, and screened for AdV 
DNA using nested PCR (2). The lower threshold of this technique described for the detection of 
AdV DNA is 3 viral genomes per 107 cells (2). Determining the precise number of infected cells 
requires at least four wells for each dilution, and the sensitivity of the assay increases with an 
increased number of dilutions, requiring a minimum of six dilutions (11). As described in Garnett 
et al. 2009, to determine the infected-cell frequency, the fraction of positive wells is plotted as a 
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function of the dilution (in number of infected cells), and a curve of best-fit generated (2). Based 
on the Poisson distribution, the point on the best-fit curve corresponding to 63% positive wells 
also corresponds to the dilution at which there is one-infected cell per well, yielding the frequency 
of infected cells in that sample. Because the viral load in a persistently-infected cell culture can 
fluctuate over time (3), this assay would need to be performed prior to each time point for every 
independent infection or biological replicate in an experiment to get an accurate number, quickly 
becoming an unwieldy and expensive endeavor with increased number of samples. 
     Another highly sensitive alternative to the limiting-dilution approach for detection is to 
use fluorescence in-situ hybridization (FISH) to detect viral genomes (12-15).  This technique is 
commonly used for detection, quantification, and spatial resolution of nucleic acid sequences, but 
implementation is not trivial. Protocols need to be developed and validated, and procedures, which 
are probe- and sample-specific, must be optimized empirically (16).  As with the limiting-dilution 
assay, the time- and cost-intensive nature of the FISH technique makes it impractical when 
multiple time-points and large numbers of samples are needed.  
    A different option for determining infected-cell frequency for persistently-infected cells 
would be incorporation of a transgene reporter into the incoming virus which would signal the 
presence of the viral genome for long periods of time. Through a generous gift from Dr. André 
Lieber at University of Washington Department of Medicine, we procured a mutant AdV-C5 virus 
with the E3 region disrupted by insertion of the GFP gene driven from the cytomegalovirus (CMV) 
major immediate early-gene promoter (MIEP), called Ad5GFP (7).  Many of the AdV early gene 
E3 protein products have been found to be dispensible for a wild-type infection phenotype in 
culture (6), and because the reporter was driven from a highly active, non-native promoter, we 
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hypothesized that this virus would 1) establish persistent infection, and 2) continuously express 
GFP in infected cells, allowing us rapid determination of infected-cell frequency in our cultures.  
4.3.1 Ad5GFP establishes persistent infection in BJAB and Jurkat cell lines, but 
GFP expression is repressed alongside AdV genes 
Two lymphocytic cell lines which support persistent infection (BJAB – B cell line and 
KE37 – T cell line) and one lymphocytic cell line, which progresses to lytic infection (Jurkat – T 
cell line), were infected with Ad5GFP, and expression of GFP and AdV hexon protein were 
measured by flow cytometry during the first 16 days of infection. As seen in Figure 4-1, peak 
expression of viral genes occurs relatively quickly (Day 6) for infected Jurkat cells, and several 
days later (Day 11) for BJAB cells, as has been previously reported (3). At these time points, 
approximately 80% of Jurkat and BJAB cells were expressing both hexon and GFP, an indication 
that the vast majority were well-infected. Surprisingly, hexon and GFP expression were never 
detected in more than 5% of KE37 cells (Figure 4-1B), an effect seen in multiple attempts to infect 
this cell line (data not shown).  The cause of these thwarted efforts to infect KE37 has not been 
determined with Ad5GFP.  
In both of the BJAB and Jurkat cell lines (Figures 4-1A and B), hexon expression was 
detected in a higher percentage of cells at the earliest time point than GFP, approximately 10% 
higher in BJAB and 20% higher in Jurkat, indicating that these genes may be subject to different 
regulation in the infected cells in the early stage of infection. However, by Day 17 post-infection 
(dpi) for BJAB, both hexon and GFP were detected in far fewer cells.  This decrease appears to 
correspond to the repression of viral genes seen as persistently-infected cells transition from the 
acute phase of infection to the persistent phase (3), and not through lysis of infected cells as 
viability remained above 90% (data not shown). Despite regulation through the CMV promoter, 
108 
the GFP was also down-regulated to approximately the same level as hexon in BJAB cells (fewer 
than 20% cells positive) and expression appears to be subject to similar mechanisms of repression. 
 
 
Figure 4-1. Percent of cells expressing GFP and hexon during acute infection with 
Ad5GFP in lymphocyte cell lines. 
A) BJAB, B) KE37, and C) Jurkat cell lines shown.  Cells were infected with MOI 50 
following standard spin protocol (see Materials and Methods), and GFP and hexon protein 
expression detected by flow cytometry at Days 3, 5, 11, and 17 post-infection. One representative 
infection of n = 2 for BJAB, n = 3 for KE37, and n = 5 for Jurkat is shown. 
 
     The Jurkat cell line typically progresses towards lysis when infected with AdV-C5 
(3,17); however, Jurkat infection with the Ad5GFP virus establishes persistence.  The Ad5GFP 
virus has no functional E3 proteins (8), including the E3-11.6-kDa Adenovirus Death Protein 
(ADP), which has been shown to be essential for lytic infection in lymphocytes (17). The lack of 
ADP expression is presumably what allows the Jurkat cells to remain infected with the Ad5GFP 
virus, but this has not been directly evaluated in this model. Although the infected Jurkat cells 
continued to express higher levels of both hexon protein and GFP than the BJAB cells, there was 
still a substantial decline in the number of cells expressing either protein by Day 17 p.i. from 80% 
at peak infection to roughly 50% (Figure 4-1C). The Ad5GFP virus thus does establish persistent 
infection in BJAB and Jurkat cells, but expression of the reporter is repressed similarly to the 
adenovirus native genes.       
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4.3.2 Repressed GFP and hexon genes respond to histone deacetylase (HDAC) 
inhibition and phorbol 12-myristate 13-acetate (PMA) ionomycin (Iono) 
treatment in persistently-infected Jurkat cells 
Ad5GFP persistent infection in Jurkat cells was sustained for over 50 days in culture with 
low viral protein and GFP-reporter expression (data not shown); similar long periods of time for 
AdV-C5 persistent infection have been documented for other lymphocytic cell lines (3,4). HDAC-
mediated repression of CMV promoter-driven transgenes delivered by AdV-based vectors has 
been documented (18), a mechanism we predicted could contribute to the silencing of the GFP 
reporter in our Ad5GFP genome.  To determine if the repression of the GFP reporter gene was 
HDAC-mediated, we treated Ad5GFP-infected Jurkat cells at Day 33 p.i. with the pan-HDAC 
inhibitor trichostatin A (TSA), and determined the percent of cells expressing GFP using 
fluorescent imaging cytometry. As shown in Figure 4-2, TSA treatment increased the number of 
GFP-positive Jurkat cells from approximately 10% to 30%, indicating that the reporter was being 
expressed in only one-third or fewer of the cells actually containing viral DNA, and that the 
repression was HDAC-regulated. In contrast, infected BJAB cells at Day 33 p.i. showed no 
detectable GFP expression before or after treatment (Figure 4-2), and as no PCR to detect viral 
genomes was performed, loss of the viral DNA cannot be ruled out. 
PMA/Iono treatment is commonly used to simulate immunoactivation of immune cells 
through induction of the T- and B-cell receptor-linked signaling pathways (19,20).  Because 
PMA/Iono treatment has been shown to upregulate viral gene expression and induce production 
of infectious virions in naturally-infected tonsillar lymphocytes (2), we wanted to see if PMA/Iono 
treatment would upregulate expression of the repressed GFP-reporter gene.  We also wanted to 
further assess if GFP expression would mirror hexon gene expression.  Persistently-infected Jurkat 
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Figure 4-2. Treatment with HDAC inhibitor TSA increases number of cells expressing GFP 
reporter gene in persistently-infected Jurkat cells. 
Infected BJAB or Jurkat cells, at 33 days p.i., were treated for 24 hours with 150nM TSA.  
Percent of cells expressing GFP was determined by fluorescent imaging cytometry. One 
experiment for each cell line was performed. 
 
cells, at Day 21 or Day 50 p.i., were treated for 24 hours with PMA/Iono, and the percent of cells 
expressing GFP or hexon protein determined by flow cytometry (Figure 4-3).   
 
 
Figure 4-3. Treatment with PMA/Ionomycin increases number of cells expressing GFP and 
hexon in persistently-infected Jurkat cells. 
Persistently-infected Jurkat cells at Day 21 p.i. (bars with black outlines) or at Day 50 p.i. 
(bars with gray outlines) were treated with PMA/Iono and percent of GFP- or hexon-expressing 
cells determined by flow cytometry. Solid bars are untreated samples, and patterned bars are 
PMA/Iono-treated.    
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The cells at Day 50 p.i. had lower percentages of both GFP- and hexon-expressing cells than 
the cultures at 21 days p.i., showing a time-dependent downward trend for viral protein expression 
similar to what has previously been reported for cell line models of persistent infection (3).  In 
untreated samples from both cultures, the number of GFP-expressing cells was substantially higher 
than the number positive for hexon.  While this discrepancy may reflect a true difference in 
expression levels, it may also reflect an inferior detection capacity of the hexon antibody compared 
to the direct detection of the expressed GFP. Interestingly, the number of GFP- and hexon-positive 
cells both approximately doubled in response to the PMA/Iono treatment, showing that both the 
reporter and the viral late gene have regulatory elements in common. These data also add additional 
support for PMA/iono signals being able to increase viral gene expression at the protein level in 
addition to the mRNA level (Chapter 2, Figure 2-2B).  In addition, these data again demonstrate 
that at least half of the untreated infected cells were not expressing detectable levels of GFP or 
hexon. 
4.4 Conclusions: Part A - Determining the Frequency of AdV-Infected Cells in a 
Persistently-Infected Cell Culture 
While we were able to establish persistent infection with the Ad5GFP virus in Jurkat cells, 
this virus is a sub-optimal reporter virus for several reasons. First, the GFP expression is repressed 
to a similar degree as the late gene hexon (Figure 4-3), so cannot give a direct measure of the 
number of infected cells. Second, the failed infection of KE37 cells (Figure 4-1) and the possible 
loss of viral DNA by Day 33 in the BJAB cell line (Figure 4-2) suggest that Ad5GFP may be less-
fit than wild-type virus for establishing persistent infections. Further characterization and 
optimization of Ad5GFP infection in BJAB and KE37 needs to be done to determine if long-term 
infection can be established in these lines.  Despite these shortcomings, the use of the reporter 
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virus to establish persist infections in combination with PMA/Iono treatment could be a potential 
means to quickly obtain an estimate of the number of infected cells without having to perform a 
time-consuming limiting-dilution assay. Additional studies to establish that persistent infections 
of KE37 and BJAB with Ad5GFP are possible, an evaluation of the responsiveness of the GFP 
reporter to PMA/Iono in these cell lines, and validation with a limiting-dilution assay need to be 
done to determine the usefulness of an Ad5GFP/PMA-Iono approach to determining the number 
of infected cells in these cultures.  In addition, these data add additional support for PMA/iono 
also being able to increase viral gene expression in infected lymphocytes. 
 
4.5 Results:  Part B - Detection of Viral Proteins in Low Abundance 
In our studies to understand the transcriptional repression of the AdV genome in 
lymphocytes, we have used several different agents, such as inhibitors and activators of known 
transcriptional repressors, and assessed the impact of those agents on viral gene expression at the 
level of transcription. Detection of mRNAs, even in very low abundance, is possible with reverse 
transcription – quantitative polymerase chain reaction (RT-qPCR) because this approach involves 
amplification of the target. To determine if changes to transcription levels are biologically relevant, 
the protein products of those viral genes should also be assessed. Detection of viral proteins in 
very low abundance can be challenging and is almost entirely dependent on the quality of available 
antibodies to target them.  
     The most commonly used technique for detection and semi-quantification of specific 
proteins in a sample is the western blot, or immunoblot, which when optimized, can detect 
picomolar amounts of target protein (21). The main limitation of western blotting is the quality of 
the antibody, which must have specificity for the target and recognize the target in partially 
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denatured form (21). While additional steps can be taken to increase detection of low-abundance 
target protein in the sample, such as enrichment through immunoprecipitation or combinatorial 
peptide ligand libraries (CPLL) or depletion of common large proteins like IgG through 
immunodepletion, these procedures either still require high-quality antibodies or are very high-
cost (22). The following sections describe our attempts to determine if low abundance viral 
proteins could be detected with available antibodies in order to assess the biological relevance of 
experimentally-induced changes to transcriptional levels of the corresponding genes.    
4.5.1 E1A proteins are not detectable in persistently infected KE37 and BJAB cell 
lines due to non-specific binding of anti-E1A antibody 
The AdV immediate early gene E1A protein products (289R and 243R) are the first 
expressed in the course of lytic infection, and essential to activating the other early genes and 
preparing the cell for viral replication (23).  Logically, E1A protein expression must be tightly 
controlled during persistent infection, but whether they function in any capacity towards 
persistence is not known. To determine if we could detect the E1A proteins in persistently-infected 
lymphocytes, we prepared cell lysates and performed western blot using the most commonly-used 
antibody against the E1A protein products (M73 clone, (24)) (Figure 4-4). In addition, we tested 
lysates from infected lymphocytes treated with the small molecule inhibitor, NSC95397, which 
disrupts C-terminal Binding Protein (CtBP) repressor complexes (25). As shown in Chapter 2, 
Figure 2-6, NSC95397 treatment induces upregulation of E1A transcription in T-cell lines, and we 
hypothesized that NSC95397 treatment would induce increases in E1A proteins as well.  
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Figure 4-4. Immunoblot for E1A in persistently-infected lymphocytes. 
Panel A: Persistently-infected cell lines, Jurkat 36 days post infection (dpi, Ad5GFP), 
KE37 and BJAB 66 dpi (AdV-C5-dl309). Each cell line was untreated or treated with 10 𝜇M 
NSC95397 for 24 hours as indicated. Positive control is Jurkat infected with Ad5GFP 36 dpi, 
which expresses wild-type E1A proteins, >20% of cells GFP+ (data not shown). Panel B: 
Uninfected cell lines, untreated or treated with 10 𝜇M NSC95397 for 24 hours. Positive control 
same as Panel A.  𝛽-actin used as loading control. 
 
As shown in Figure 4-4A, E1A protein could be detected in persistently-infected Jurkat 
cells (which served as our positive control), and was dramatically down-regulated by NSC95397 
treatment. Bands of similar size to the E1A protein products were also detected in the infected 
KE37 and BJAB cell lines, but at much lower levels. To determine whether the proteins detected 
in the infected KE37 and BJAB cell lysates were E1A or not, a panel of uninfected cell lysates, 
with or without NSC95397 treatment were run as shown in Figure 4-4B. Non-specific binding of 
the E1A antibody could be detected in the same protein-size range in all lymphocyte cell lysates. 
As a result we could not differentiate between low amounts of E1A protein and non-specific 
binding of the antibody.  
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4.5.2 E2 DNA-binding protein is detectable in persistently-infected T cell lines 
To see if detection of other AdV early genes in persistently-infected cells was possible, a 
western blot targeting the E2 DNA-binding protein (DBP) was performed on the same persistently-
infected cell lines untreated or treated with NSC95397 (Figure 4-5). The E1A 289R protein is 
essential for the transactivation of the E2 early gene. This gene encodes the viral DNA polymerase, 
DBP, and the precursor terminal protein, which are all needed for viral DNA replication (26,27).  
Figure 4-5A shows the detectable E2 DBP in persistently-infected lymphocytic cells lines 
compared to acutely infected A549 epithelial cells (first column). DBP could be detected with a 
strong signal in both persistently-infected T cell lines (Jurkat and KE37), with a substantially 
higher amount present in the Jurkat cells. The E2 proteins from infected lymphocytes appear to 
have migrated at a slower rate than those in A549 lysates, suggesting the presence of some post-
translational modifications not present in the epithelial cell line (Figure 4-5A). NSC95397 
treatment does appear to slightly upregulate DBP in both T cells lines as well, suggesting that 
CtBP complexes may play a role in repressing E2 expression at the protein level. The E2 
immunoblot of uninfected cell lysates (Figure 4-5B) shows that, like the E1A antibody, the E2 
antibody also binds non-specifically to cellular proteins of roughly the same size as the viral target. 
Interestingly, DBP could not be detected in infected BJAB cells above the background levels 
(uninfected cells shown in Figure 4-5B), despite detectable levels of the E2 transcript (data not 
shown). 
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Figure 4-5. E2 DNA-binding protein is detectable in persistently-infected T cells. 
Panel A: Acutely infected A549 cells at 2 days post-infection (dpi, AdV-C5-dl309), 
persistently-infected cell lines, Jurkat 36 dpi (Ad5GFP), KE37 and BJAB 66 dpi (AdV-C5-dl309). 
Each cell line (except A549) was untreated or treated with 10 𝜇M NSC95397 for 24 hours as 
indicated. Two positive controls are acutely infected A549 and Jurkat infected with Ad5GFP 36 
dpi, >20% of cells GFP+ (data not shown). Panel B: Uninfected cell lines, untreated or treated with 
10 𝜇M NSC95397 for 24 hours. Positive control is untreated infected KE37 shown in Panel A.   
 
 
4.6 Conclusions:  Part B - Detection of Viral Proteins in Low Abundance 
Expression of AdV hexon (3) and E3 (ADP, (17)) have been shown to be repressed in 
persistently-infected lymphocytic cell lines at both the transcriptional and post-transcriptional 
levels.  To fully characterize these mechanisms of repression and those repressive mechanisms 
acting at other AdV genes, detection of changes in gene expression at both the transcript and 
protein levels is important. Through the use of RT-qPCR, low abundance transcripts can be 
detected, but detection of low abundance proteins remains problematic. Our initial attempts have 
revealed that the commonly used E1A monoclonal antibody (clone M73), binds to multiple 
lymphocyte proteins of the same approximate size as the E1A proteins in uninfected lymphocytic 
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cell line extracts (Figure 4-4B), potentially masking any signal from low abundance E1A proteins 
and making interpretation difficult.   
     The E2 DBP protein appears the be more highly expressed and therefore easily 
detectable in persistently-infected T cell lines than E1A.  Although to a lesser degree than the E1A 
M73 antibody, the E2 DBP B6-8 antibody also shows binding to cellular proteins of the same 
approximate size as the DBP protein (Figure 4-5B), again making any weak signals difficult to 
interpret. 
4.7 Future Work 
To decrease variability across experiments and to gain a more complete understanding of 
the dynamics of persistent adenovirus infection of lymphocytes, the capacity to detect and quantify 
viral genomes on a single cell basis will be critical for future work. Development and optimization 
of a viral genome-embedded reporter which is not subject to transcriptional repression and which 
can be easily detected without amplification would be ideal, but clearly this is no easy feat.  To 
determine whether viral proteins are being expressed in low abundance, more specific antibodies 
are needed. Establishing persistent AdV infections with viruses engineered to express tagged viral 
proteins, such as MYC or FLAG, may be a way to determine viral protein expression in low 
abundance in future work. 
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5 CONCLUSIONS AND FUTURE STUDIES 
5.1 Discussion 
Pediatric patients receiving hematopoietic stem cell transplants (HSCT) are at significant 
risk for developing disseminated adenovirus (AdV) infection, with AdV-related post-
transplantation mortality between 3.2 and 6.0% (1,2).  For the most severely immunocompromised 
patients, reactivation of latent adenovirus from persistently-infected lymphocytes is the 
predominant cause of a deadly viremia (2).  The mechanisms that allow the virus to persist, or 
those that induce reactivation, are almost entirely unknown. 
The goal of this doctoral work was to elucidate the cellular mechanisms contributing to the 
maintenance of the persistent AdV infection of lymphocytes. More specifically, this work focuses 
on the transcriptional repression of the viral genome that is present during persistent infection and 
the roles that cellular transcriptional repressors Class I, II, and III HDACs and the CtBPs play in 
repressing AdV genes.  This work further focuses on how the CtBPs might link viral gene 
expression to the metabolic state of the lymphocyte, as vast metabolic changes are a defining 
characteristic of this cell type. The findings presented within this dissertation are the first studies 
that have characterized the contribution of these proteins in the persistent AdV infection of 
lymphocytes and provide novel insight into cellular requirements for establishment of the 
persistent infection and possible mechanisms for reactivation. 
In Chapter 2, we demonstrated that in persistently-infected lymphocytic cell lines 
transcription of viral genes is repressed compared to lytically-infected cells with similar levels of 
viral DNA (Figure 2-1A and B).  Our studies focused on viral immediate early gene E1A, early 
gene E3, and late gene hexon as representative viral genes expressed at key points in the viral life 
cycle, and we were surprised to find that the relative proportions of those transcripts were 
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maintained between persistent and lytic infection (Figure 2-1C).  However, a more complete 
analysis of the viral transcriptome may give further insight into lymphocyte-specific 
transcriptional regulation that might play a role in persistence.  Using deep cDNA sequencing, 
Zhao et al. (2014) recently confirmed fifty distinct viral mRNAs are produced during lytic 
infection, some of which had not previously been identified (3). Several viral genes have been 
reported to display alternative patterns of expression when compared to lytic infections, suggesting 
specific programs of repression are present in persistent infections of lymphocytes (4-6). It is likely 
that expression of additional viral gene products is altered in persistent infection as well, and a 
robust screening of the complete viral transcriptome of persistently-infected cells could identify 
genes which require altered expression to establish persistence.    
In Chapter 3, the roles of Class I, II, and III HDACs in repression of viral genes were 
investigated.  Inhibition of Class I HDAC enzymatic activity upregulated E3 and hexon in both B 
and T cell lines, but increased E1A expression only in the T cell line (Figure 3-3). Inhibition of 
Class II enzymatic activity did not induce any upregulation in viral gene expression (Figure 3-4), 
but deacetylase function is considered less relevant for Class II HDACs compared to their 
constituency in repressor complexes and nuclear-cytoplasmic shuttling (7,8).  Although Class I 
HDACs were uniformly expressed across our cell line models of infection, Class II HDACs were 
not (Figure 3-2). In particular, expression of Class II HDAC7 correlated with repression of AdV 
gene expression (Figures 3-2 and 2-1B).  HDAC7 is more highly expressed in cells of lymphoid 
background and is important to lymphocyte development (9).  Studies of infection paired with 
shRNA knock-down of HDAC7 in lymphocytes or overexpression of HDAC7 in epithelial cells 
could give further insight into a possible role of HDAC7 in repression of AdV gene expression.  
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Class III HDACs (sirtuins) were found to be involved in repression of late gene hexon 
expression in both B and T cell lines (Figures 3-5 and 3-6). This activity may account for the 
reduction in viral titers reported with treatment of sirtuin-activator resveratrol (10). Interestingly, 
activation of SIRT1 appears to up-regulate expression of E1A (Figure 3-6).  Gupta et al. (2013) 
have shown that the E1A promoter is regulated, in part, by retention of viral protein VII; the 
presence of protein VII at the E1A promoter and surprisingly H4 acetylation suppressed E1A 
expression (11). The H4Ac and resulting repression at the E1A promoter appeared to be incurred 
through activity of cellular HAT Tip60. As Tip60 is a target for SIRT1 deacetylation (12), which 
results in reduced activity, it is possible that SIRT1 activation may upregulate E1A through 
targeting of Tip60. The activity of SIRT1 at the E1A promoter, in both lymphocytes and epithelial 
cells, requires additional study to fully identify the mechanisms involved.  
In addition to the contribution of Class I, II, and III HDACs toward the transcriptional 
repression seen in persistent infection, we have also shown that this repression and reactivation 
may be tied to the metabolic state of the lymphocyte. Immunoactivation of tonsillar lymphocytes 
has been shown to reactivate latent AdV causing increases in viral gene expression and productive 
infection (13). In previous studies, a cocktail of immune cell stimulators was used including PMA, 
Ionomycin, IL-2, anti-CD3 and anti-CD28, however, no specific mechanisms for viral gene de-
repression were determined (13).  In Chapter 2, we confirmed that immunoactivation of 
lymphocytic cell lines with PMA/Iono upregulates viral gene expression (Figure 2-2B).  Activation 
of lymphocytes has been shown to shift concentrations of NAD+, its reduced form NADH, and 
other key intermediary metabolites, many-fold to meet demands of biosynthetic pathways for 
differentiation and proliferation (14-20). The NAD+/NADH ratios of the lymphocytic cell lines 
similarly increase in response to PMA/Iono activation (Figure 2-3A), and increasing the 
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NAD+/NADH ratio directly through nicotinamide treatment did increase viral gene expression as 
well (Figure 2-4B). Thus, our data support the notion that changes in the metabolic status of 
lymphocytes can promote reactivation of AdV gene expression.   
Understanding how the NAD+/NADH ratio is mechanistically tied to viral gene expression 
will require additional work.  NAD+ is used as a co-substrate for a number of enzymes including 
poly(ADP-ribose) polymerases (PARPs), sirtuins, and cyclic ADP-ribose synthases (cADPRSs) 
(21). We have shown that NAD+-dependent sirtuins are involved in the transcriptional repression 
of the viral genome in lymphocytes (Figures 3-6 and 3-7), but the involvement of other NAD+-
dependent enzymes in the regulation of viral gene expression during either lytic or persistent 
infection is incompletely understood or has yet to be studied.  One of the only other NAD+-
dependent enzymes to have been studied in lytic infection is DNA-dependent PARP1; the AdV 
E4orf4 protein has been found to increase production of viral progeny through inhibition of 
PARP1, which is activated by the infection-induced DNA damage response (DDR) (22).  E4orf4 
inhibition of PARP1 activity was speculated to prevent PARP1-induced depletion of NAD+ and 
the resulting necrotic death, although whether AdV infection induces death by this pathway has 
not been established (22). However, PARP-induced synthesis and attachment of long poly(ADP-
ribose) chains to proteins has been shown to regulate cellular transcription through chromatin 
remodeling and modification of transcription factors (23,24). Studying PARP activity, its 
interaction with E4orf4, and shifts to the NAD+/NADH ratio in the context of persistent infection 
may provide further insight into how viral transcription is linked to activation of immune cells.  
We have also shown that the NAD+/NADH ratio appears to be reduced in persistently-
infected lymphocyte cell lines, although statistical significance was not reached (Figure 2-3B). 
This is the first study suggesting that persistent AdV infection may sustainably alter the 
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metabolism of the host cell. In the course of lytic infection cellular metabolism is necessarily 
altered to produce metabolic precursors. AdV E4orf1 and E4orf6 proteins bind to MYC and E4orf4 
activates the mTOR pathways to activate transcription of genes important for increased glycolysis, 
ribose synthesis, and protein synthesis (25,26). How persistent AdV infection could 
mechanistically modulate cellular metabolism is unclear. Latent infections of other DNA viruses 
have been shown to alter cellular metabolism. KSHV expresses virally-encoded miRNAs, which 
increase the rate of glycolysis and fatty acid synthesis, an effect shown to prevent apoptosis of 
latently-infected cells (27,28). EBV infection also increases the rate of glycolysis to avoid cell 
death in latently-infected cells, an effect modulated by the viral latent membrane protein 1 (LMP-
1) protein (29). Persistent adenovirus infection of B-lymphocytes has been shown to significantly 
down-regulate several cellular genes [BBS9, BNIP3, BTG3, CXADR, SLFN11, and SPARCL (30)], 
however, none are reported to obviously function in the regulation of metabolism. It is possible 
that some of the other genes identified as altered by AdV infection, such as dual specificity 
phosphatase 1 (DUSP1), protein tyrosine phosphatase non-receptor 12 (PTPN12), and 
serine/threonine kinase 4 (STK4), which all function in mitogen-activated protein kinase (MAPK) 
signaling, could play a role in this effect [(30), supplemental data therein]. MAPK signaling links 
environmental stimuli to several metabolic processes, but whether this pathway is involved in 
metabolic changes caused by AdV infection remains to be determined.  Characterizing the full 
repertoire of viral gene products expressed during the persistent AdV infection will be an important 
step towards identifying any viral regulators of cellular metabolism important for establishment or 
maintenance of persistence.  
The role of the NAD-dependent CtBP-E1A interaction in the lytic AdV life cycle is 
complex and has been reported to be either repressive or faciliatory, depending on the context. Our 
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experiments using the small molecule inhibitor NSC95397 to disrupt CtBP complexes suggest that 
CtBP1, which is the only CtBP homolog detectable in our lymphocytic cell lines (Figure 2-5A), 
may play a previously unidentified role in repression of E1A in the persistent infection of T cells 
while potentiating hexon expression (Figure 2-6, A-C). CtBP repressor complexes contain many 
different chromatin modulators including Class I and II HDACs, histone methyltransferases, E3 
ligases and other transcriptional regulators which target cellular promoters (31-34). Whether CtBP 
repressor complexes occupy the E1A promoter in persistent infection needs to be directly 
determined. Additionally, it is currently unclear if persistently-infected lymphocytes express either 
the E1A-289R or the -243R proteins, despite detectable levels of mRNAs, because of high levels 
of non-specific binding of currently available E1A antibodies (Figure 4-4). A recent study of E1A 
13S and 12S mRNAs in single cells revealed that the 13S splice variant was favored in cells 
containing lower numbers of viral genomes (4). Both E1A-289R and E1A-243R interact with 
CtBP, however, the CR3 region is present only in the longer E1A isoform. This region offers 
interaction with different and additional binding partners, so it seems likely that the composition 
of CtBP complexes could be different depending on which E1A protein was more highly expressed 
in the infected host cell. Pull-down and chromatin immunoprecipitation assays to analyze CtBP1 
complex composition and promoter occupancy in persistently-infected lymphocytes could give 
further insight into how CtBP1 may be functioning in viral gene repression.   
Finally, the experiments examining viral gene expression through the analysis of E1A, E3, 
and hexon have revealed that the E1A promoter is responsive to different stimuli in persistently-
infected lymphocytes than the E3 and major late promoters (Figures 2-2B, 2-4B, 2-6B and C, 3-4, 
3-6, 3-7). This is not entirely unexpected, as these promoters contain different known regulatory 
elements (Table 1-2). The structure of the different promoters must necessarily be intricately tied 
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to the optimal temporal regulation of viral transcription. However, with the exception of the E3 
promoter (35), study of the AdV promoters has been done almost entirely in the context of lytic 
infection of epithelial cells. Yet, the AdV genome and the regulatory elements therein must have 
evolved to optimize both the lytic infection and the persistent infection, the later being the key 
phase of the viral life cycle keeping the virus circulating in the population.  Because immediate 
early gene E1A is critical for both activating other viral genes and for preparing the host cell for 
viral replication, the regulation of E1A needs to be considered and investigated from the 
perspective of both lytic and persistent infection.  E1A must be carefully regulated in cells that do 
not progress towards lysis, and chromatinization of the E1A promoter may be important for long-
term infection and for potentiating reactivation.  Future studies of persistent AdV infection of 
lymphocytes should focus on characterizing the state of the viral chromatin at the E1A promoter.   
In conclusion, this doctoral work has contributed to the knowledge of mechanisms 
regulating transcriptional repression of the AdV genome in persistently-infected lymphocytes. 
Clearly, many unanswered questions remain, and no doubt this field will continue to be an exciting 
area of research, with many novel mechanisms waiting to be discovered that have allowed this 
virus to maintain both its well-known lytic infection and its more enigmatic persistent infection.  
Understanding the mechanisms for adenoviral persistence and reactivation may provide novel 
targets for therapies to prevent reactivation and disseminated adenoviral infection in pediatric 
HSCT recipients. 
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APPENDICES  
Cell viability and density with different treatment drugs 
For the appendices A-E, cells were plated a density of 3 X 105 cells/mL and density and 
viability determined at times indicated using Trypan blue exclusion. All experiments were run in 
triplicate. Error bars show standard deviation. Concentrations indicated on individual graphs.  
Appendix A – Nicotinamide treatment 
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Appendix B – Trichostatin A (TSA) treatment 
 
Bar Graph: Cell Density, Line Graph: Viability 
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Appendix C – Tacedinaline treatment 
 
Bar Graph: Cell Density, Line Graph: Viability 
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Appendix D – TMP195 treatment 
 
Bar Graph: Cell Density, Line Graph: Viability 
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Appendix E – NSC95397 treatment 
 
Dashed gray line demarks 40% viability. Bar Graph: Cell Density, Line Graph: Viability  
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Appendix F – Tubacin treatment 
 
Bar Graph: Cell Density, Line Graph: Viability 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0.0E+00
2.5E+05
5.0E+05
7.5E+05
1.0E+06
1.3E+06
1.5E+06
Untreated 1uM 2uM 4uM
Vi
ab
ili
ty
C
el
l D
en
si
ty
 (c
el
ls
/m
L)
KE37: 24 Hours Tubacin, n = 3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0.0E+00
2.5E+05
5.0E+05
7.5E+05
1.0E+06
1.3E+06
1.5E+06
Untreated 1uM 2uM 4uM
Vi
ab
ili
ty
C
el
l D
en
si
ty
 (c
el
ls
/m
L)
KE37: 48 Hours Tubacin, n = 3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0.0E+00
2.5E+05
5.0E+05
7.5E+05
1.0E+06
1.3E+06
1.5E+06
Untreated 1uM 2uM 4uM
Vi
ab
ili
ty
C
el
l D
en
si
ty
 (c
el
ls
/m
L)
Jurkat: 24 Hours Tubacin, n = 3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0.0E+00
2.5E+05
5.0E+05
7.5E+05
1.0E+06
1.3E+06
1.5E+06
Untreated 1uM 2uM 4uM
Vi
ab
ili
ty
C
el
l D
en
si
ty
 (c
el
ls
/m
L)
JURKAT: 48 Hours Tubacin, n = 3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0.0E+00
2.5E+05
5.0E+05
7.5E+05
1.0E+06
1.3E+06
1.5E+06
Untreated 1uM 2uM 4uM
Vi
ab
ili
ty
C
el
l D
en
si
ty
 (c
el
ls
/m
L)
BJAB: 24 Hours Tubacin, n = 3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
0.0E+00
2.5E+05
5.0E+05
7.5E+05
1.0E+06
1.3E+06
1.5E+06
Untreated 1uM 2uM 4uM
Vi
ab
ili
ty
C
el
l D
en
si
ty
 (c
el
ls
/m
L)
BJAB: 48 Hours Tubacin, n = 3
136 
Appendix G – Resveratrol treatment 
 
Bar Graph: Cell Density, Line Graph: Viability 
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Appendix H – Sirtinol treatment 
 
 
Bar Graph: Cell Density, Line Graph: Viability 
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Jurkat: 24 Hours Sirtinol Tx, n = 3
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Jurkat: 48 Hours Sirtinol Tx, n = 3
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BJAB: 24 Hours Sirtinol Tx, n = 3
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BJAB: 48 Hours Sirtinol Tx, n = 3
